CA2316223A1 - Hydrophilic coating for an intracorporeal medical device - Google Patents
Hydrophilic coating for an intracorporeal medical device Download PDFInfo
- Publication number
- CA2316223A1 CA2316223A1 CA002316223A CA2316223A CA2316223A1 CA 2316223 A1 CA2316223 A1 CA 2316223A1 CA 002316223 A CA002316223 A CA 002316223A CA 2316223 A CA2316223 A CA 2316223A CA 2316223 A1 CA2316223 A1 CA 2316223A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- halo
- hydroxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
- A61L29/048—Other specific proteins or polypeptides not covered by A61L29/045 - A61L29/047
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0056—Catheters; Hollow probes characterised by structural features provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir
Abstract
It has been discovered that compositions which are blends or mixtures including a monomeric fatty acid component can serve as stable lubricity additives in distillate fuels, including gasoline. The compositions may include saturated or unsaturated, monomeric fatty acids having from 12 to 22 carbon atoms; a synthetic monomeric acid having from 12 to 40 carbon atoms; and saturated or unsaturated, oligomeric fatty acids having from 24 to 66 carbon atoms. Where a saturated monomeric fatty acid is used, a hindered and/or tertiary amine may be present as a stabilizer.
Description
HETEROCYCLIC TOPOISOMERASE POISONS
Ba , gromd of the Invention DNA-topoisomerases are enzymes present in the nuclei of cells where they catalyze the breaking and rejoining of DNA strands, controlling the topological state of DNA. Recent studies also suggest that topoisomerases are involved in regulating template supercoiling during RNA transcription. There are two major classes of mammalian topoisomerases. DNA-topoisomerase-I
catalyzes changes in the topological state of duplex DNA by performing transient single-strand breakage-union cycles. In contrast, mammalian topoisomerase II alters the topology of DNA by causing a transient enzyme bridged double-strand break, followed by strand passing and resealing.
Mammalian topoisomerase II has been further classified as Type II a and Type II
(3. The antitumor activity associated with agents which are topoisomerase poisons is associated with their ability to stabilize the enzyme-DNA cleavable complex. This drug-induced stabilization of the enzyme-DNA cleavable complex effectively converts the enzyme into a cellular poison.
Several antitumor agents in clinical use have potent activity as mammalian topoisomerase II poisons. These include adriamycin, actinomycin D, daunomycin, VP-16, and VM-26 (teniposide or epipodophyllotoxin).
In contrast to the number of clinical and experimental drugs which act as topoisomerase II poisons, there are currently only a limited number of agents which have been identified as topoisomerase I poisons. Camptothecin and its structurally-related analogs are among the most extensively studied topoisomerase I poisons. Recently, bi- and terbenzimidazoles (Chen et al., Cancer Res. 1993, 53, 1332-1335; Sun et al., J. Med. Chem. 1995, 38, 3638-3644; Kim et al., J. Med. Chem. 1996, 39, 992-998), certain benzo[c]phenanthridine and protoberberine alkaloids and their synthetic analogs (Makhey et al., Med. Chem. Res. 1995, S, 1-12; Janin et al., J. Med. Chem 1975, 18, 708-713; Makhey et al., Bioorg. & Med Chem. 1996, 4, 781-791), as well as the fungal metabolites, bulgarein (Fujii et al., J. Biol. Chem. 1993, 268, 131b0-13165) and saintopin (Yamashita et al., Biochemistry 1991, 30, 5838-5845) and indolocarbazoles (Yamashita et al., Biochemistry 1992, 31, 12069-12075) have been identified as topoisomerase I poisons.
Presently, a need exists for novel anti-cancer agents, for anti-cancer agents that exhibit improved activity, and for anti-cancer agents that exhibit fewer side-effects or improved selectivity compared to existing agents.
The present invention provides compounds that exhibit inhibitory activity against topoisomerase I, and compounds that are effective cytotoxic agents against cancer cells, including drug-resistant cancer cells.
Accordingly there is provided a compound of the invention which is a compound of formula I:
(I) wherein R, and R2 are each independently hydrogen, (C,-C6)alkyl, (C3-C~cycloalkyl, (C,-C~alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, halo, (C3-C~cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ
C6)alkanoyloxy, aryl or heteroaryl; or R, and RZ taken together are methylenedioxy; or R, and RZ taken together are benzo; wherein any aryl, heteroaryl, or benzo may optionally be substituted by l, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-Cbkycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyioxy, and halo;
R3 is hydrogen, (C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyloxy, or halo; and R4 and RS taken together are a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo;
wherein each X is independently absent or is H, O, (C,-C4)alkyl, phenyl or benzyl; and wherein at least one (e.g. 1 or 2) of said chain members is an N-H
group;
or a pharmaceutically acceptable salt thereof;
provided R4 and Rs taken together are not -N(H)-C(H~N-.
Preferrably, any carbon of R4 and R3 is saturated (-CHZ-) or unsaturated (=CH-).
The invention also provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
The invention also provides a therapeutic method comprising inhibiting cancer cells by administering to a mammal (e.g. a human) in need of such therapy, an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective to inhibit said cancer cells.
The invention also provides a method comprising inhibiting cancer cells by contacting said cancer cells in vitro or in vivo with an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective to inhibit said cancer cells, i.e. to inhibit their activity, such as their ability to divide, migrate, or proliferate.
The invention also provides a compound of formula I for use in medical therapy (preferably for use in treating cancer, e.g. solid tumors), as well as the use of a compound of formula I for the manufacture of a medicament useful for the treatment of cancer, e.g. solid tumors.
The invention also provides processes and novel intermediates disclosed herein which are useful for preparing compounds of the invention.
Some of the compounds of formula I are useful to prepare other compounds of formula I.
FIG. 1 Illustrates the synthesis of compounds of the invention (2 and 3) and the synthesis of compound 4.
FIG. 2 Shows the structure of compound 5.
The following definitions are used, unless otherwise described:
halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl"
embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, {C,-C,)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a bent-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymoiphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine topoisomerase poisoning activity or cytotoxic activity using the standard tests described herein, or using other similar tests which are well known in the art.
Specific and preferred values listed below 'for radicals, substituents, and ranges; are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents Specifically, (C,-C6)alkyl can be methyl, ethyl, propyl; isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C3-C6)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; (C3 C6)cycloalkyl(C,-C6)alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl; (C,-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy;(C,-C6)alkanoyl can be acetyl, propanoyl or butanoyl; halo(C,-C6)alkyl can be iodomethyl, bromomethyl, chloromethyl, fluoromethyl, trifluoromethyl, 2-chloroethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, or pentafluoroethyl;
hydroxy(C,-Cb)alkyl can be hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6-hydroxyhexyl; (C,-C6)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexyloxycarbonyl; {C,-C6)alkylthio can be methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, pentylthio, or hexylthio; (C2-C6)alkanoyloxy can be acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy; aryl can be phenyl, indenyl, or naphthyl; and heteroaryl can be furyl, imidazoiyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N
oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N
oxide) or quinolyl (or its N-oxide).
A specific value for R, is hydrogen, halo, aryl or heteroaryl;
wherein any aryl or hetemaryl may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-C6}cycloalkyl, (C,-Cb)alkoxy, nitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, and halo.
A specific value for R~ is hydrogen, halo, aryl or heteroaryl;
wherein any aryl or heteroaryl may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of {C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ C6)alkanoyloxy, and halo.
Specifically, R, and R2 taken together can be methylenedioxy.
Specifically, R, and RZ taken together can be benzo, which benzo may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ C6)alkanoyloxy, and halo.
A specific value for R3 is hydrogen. Another specific value for R3 is (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyloxy, or halo.
Specifically, R4 and RS taken together can be -N(H)-N=N-, -N(H)-N(H)-CHZ-, -N(H)-N(H)-CH2-CHI-, -N(H)-CHZ-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-CHZ-, -N(H)-CHZ CHZ-N(H)-, -N(H)-CH,-CH2-O-, -N(H)-CHZ-CHZ S-, -N(H)-CHZ-CHZ-CH2-N(H)-, -N(H)-CH2-CHZ-CHI-O-, -N(H)-CHI-CHZ-CHZ-S-, -N(H)-CHZ-CH2-N(H)-CHZ-, -N(H)-CH2-CHZ-O-CHZ , -N(H)-CHZ-CHZ S-CHZ , -N(H)-C(=O)-C(-0)-CHZ-, -N(H)-C(-0)-C(-0)-N(H)-, -N(H)-C(-0)-C(~)-O-, -N(H)-C(=O)-C(=O)-S-, -N(H)-C(=O)-CHz-CHi , -N(H)-CHZ-N(H)-C(~)-, -CHZ-S-CHZ-N(H)-, -CHZ-N(H)-CHZ-S-, -CHz N(H)-CHZ , -CHZ-CHZ-N(H)-CHZ , -CHZ-CHZ CHZ-N(H)-CHz-, -CHZ-N(H)-CHZ-CHZ-O-, or -CHZ-N(H)-CHZ-CHZ-S-.
More specifically, R4 'and Rs taken together can be -N(H)-N=N-, -N(H)-CHZ-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-, -N(H)-CHZ-CH2 CHZ-CHZ-, -N(H)-CHZ-CHZ-N(H)-, -N(H)-CHZ CHZ-O-, -N(H)-CHZ-CHZ-S-, -N(H)-CH2-CHZ-CHZ-N(H)-, -N(H)-CHZ-CHZ-CHZ-O-, -N(H)-CHZ CHZ-CHZ-S-, or -N(H)-C(=O)-C(~)-N(H)-.
Preferably, R4 and RS taken together are -N(H)-N=N-, -N(H)-C(=O)-C{=O)-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHz-, -N(H)-CHZ-CH; CHz-, or -N(H)-CHz-CHZ-N(H)-. More preferably, R4 and RS
taken together are -N(H)-N=N- or -N(H)-C(=O)-C(=O)-N(H)-.
A preferred group of compounds of formula I are compounds wherein R, and RZ are not both hydrogen.
Another preferred group of compounds of formula I are compounds wherein R, and RZ are each independently halo (e.g. bromo).
A preferred compound of formula I is a compound of formula III:
Rz ~ I N / ~ N
R~ N
N ~I
(III) wherein R,-R5 have any of the values defined herein for a compound of formula I.
Processes for preparing compounds of formula I are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified.
A compound of formula I wherein R4 and R5 taken together are -N(H)-N=N- can be prepared from a corresponding intermediate of formula II
(II) by treatment with NaNOz under acidic conditions. Suitable conditions for performing such a transformation are described in Example 1.
A compound of formula I wherein R4 and Rs taken together are -N{H)-C(=O)-C(=O)-N(H)- can be prepared from a corresponding compound of WO 99/3382.1 PCTNS98/27822 formula II by treatment with oxalic acid under acidic conditions. Suitable conditions for performing such a transformation are described in Example 2.
An intermediate useful for preparing a compound of formula I is an intermediate of formula II.
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion;
for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be made.
The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1 % of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin;
excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fivctose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage foam. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac ar sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage foam should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition; the active compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance 5 of the required particle size in the case of dispersions or by the use of surfactants.
The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride.
10 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, aleohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art;
for example, see Jacquet et al. (IJ.S. Pat. No. 4,608,392), Geria (U.S. Pat. No.
4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No.
4,820,508).
Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models.
Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compounds) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt%.
The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mglkg/day.
The compound is conveniently administered in unit dosage form;
for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about WO 99/33824 PC'f/US98/27822 75 pM, preferably, about 1 to 50 pM, most preferably, about 2 to about 30 ~M.
This may be achieved, for example, by the intravenous injection of a 0.05 to 5%
solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
The ability of a compound of the invention to effect topoisomerase I mediated DNA cleavage can be determined using pharmacological models that are well known to the art, for example, using a model like Test A described below.
Test A. Topoisomerase I cleavage assay.
Representative compounds of the invention were evaluated in a cleavage assay using recombinant topoisomerases I. This assay was preformed as described by B. Gatto et al. Cancer Res., 1996, 56, 2795-2800. Human topoisomerase I was isolated as a recombinant fusion protein using a T7 expression system. Plasmid YEpG was purified by the alkali lysis method followed by phenol deproteination and CsCI/ethidium isopycnic centrifugation as described by Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning, a Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY
1982; pp 149-185. The end-labeling of the plasmid was accomplished by digestion with a restriction enzyme followed by end-filling with Klenow polymerase as previously described by Liu, L. F.; Rowe, T. C.; Yang, L.;
Tewey, K. M.; Chen, G. L. "Cleavage of DNA by mammalian topoisomerase II," J. Biol.
Chem. 1983,158, 15365. ICso values were calculated after 4 days of continuous drug exposure. Topoisomerase I cleavage values are reported as REC, Relative Effective Concentration (i.e., concentrations relative to compound 5, whose value is arbitrarily assumed as 1) that is able to produce the same cleavage on the plasmid DNA in the presence of human topoisomerase I.
The cytotoxic effects of a compound of the invention can be determined using pharmacological models that are well known to the art, for example, using a model like Test B described below.
Test B. Cytotoxicity assay.
Cytotoxicity was determined using the MTT-microtiter plate tetrazolinium cytotoxicity assay (MTA) (See Chen A.Y. et al. Cancer Res. 1993, 53, 1332; Mosmann, T. J., J. Immunol. Methods 1983, 65, 55; and Carmichael, J.
et al. Cancer Res. 1987, 47, 936). The human lymphoblast RPMI 8402 and its camptothecin-resistant variant cell line, CPT-KS were provided by Dr. Toshiwo Andoh (Aachi Cancer Center Research Institute, Nagoya, Japan) (see Andoh, T.;
Okada, K. "Drug resistance mechanisms of topoisomerase I drugs," Adv. in Pharmacology 1994, 29B, 93. The cytotoxicity assay was performed using 96-well microtiter plates. Cells were grown in suspension at 37 °C in 5%
COZ and maintained by regular passage in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (0.1 mg/mL). For determination of ICso, cells were exposed continuously with varying concentrations of drug and MTT assays were performed at the end of the fourth day.
Data from Test A and Test B is shown in Table 1 for representative compounds of the invention.
Table 1. Pharmacological Activity of Compounds of the Invention Cytotoxicity ICso (pM) Compound DNA clea a RPMI CPT-KS
a 5 1 0.09 0.70 2 1 0.47 _ 0.47 3 1 2.3 21 4 - 20 >20 Topo I-mediated b Compounds of formula I are potent topoisomerase I poisons.
Additionally, compounds of formula I exhibit cytotoxic activity against RPMI
8402 cancer cells and camptothecin resistant CPT-KS cells. Accordingly, compounds of formula I are useful as cytotoxic agents, for the treatment of S cancers, and in particular, solid mammalian tumors or hematologic malignancies.
Compounds of the invention are also useful as pharmacological tools for in vitro and in vivo study of topoisomerase function and activity.
Comparison of the data for compounds 2 and 3 with the data for compound 4 suggests that topoisomerase poisoning activity and cytotoxic activity improve when R4 and RS taken together are a chain comprising a H
bonding functionality (e.g. N-H). Thus, the invention provides compounds of formula I wherein R4 and Rs taken together are a chain that comprises at least one N-H group.
As used herein, the term "solid mammalian tumors" includes cancers 1 S of the head and neck, lung, mesothelioma, mediastinum, esophagus, stomach, pancreas, hepatobiliary system, small intestine, colon, rectum, anus, kidney, ureter, bladder, prostate, urethra, penis, testis, gynecological organs, ovarian, breast, endocrine system, skin central nervous system; sarcomas of the soft tissue and bone; and melanoma of cutaneous and intraocular origin. The term "hematological malignancies" includes childhood leukemia and lymphomas, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia, plasma cell neoplasm and cancers associated with AIDS. The preferred mammalian species for treatment are humans and domesticated animals.
2S The invention will now be illustrated by the following non-limiting Examples, wherein unless otherwise stated: melting points were determined with a Thomas-Hoover Unimelt capillary melting point apparatus; column chromatography refers to hash chromatography conducted on SiliTech 32-63 pm, (ICN Biomedicals, Eschwegge, Ger.) using the solvent systems indicated;
infrared spectral data (IR) were obtained on a Perkin-Elmer 1600 Fourier transform spectrophotometer and are reported in cm''; proton ('H NMR) and carbon (~;C NMR) nuclear magnetic resonance were recorded on a Varian Gemini-200 Fourier Transform spectrometer; NMR spectra (200 MHZ ~H and SO
WO 99/33824 PCT/US98/Z7$22 MHZ'3C) were recorded in the deuterated solvent indicated with chemical shifts reported in 8 units downfield from tetramethylsilane (TMS); coupling constants are reported in hertz (Hz); mass spectra were obtained from Washington University Resource for Biomedical and Bio-organic Mass Spectrometry within 5 the Department of Chemistry at Washington University, St. Louis, MO; and combustion analyses were performed by Atlantic Microlabs, Inc., Norcross, GA, and were within t 0.4% of the theoretical value.
Fxarn lie 1__ 5-Phenyl-2'-(benzotriazol-5-yl)-bibenzimidazole (2).
10 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole (1), (58 mg, 0.14 mmol) was dissolved in O.IN HCI. This solution was placed in an ice bath and while maintaining a reaction temperature below 10 ° C. NaNOz ( 10.2 mg) in 5 mL water was added dropwise. The reaction mixture was stirred for I S minutes, neutralized with O.1N KOH, 15 extracted with ethyl acetate, and the resulting material was purified by chromatography, with 10% methanol:ethyl acetate as the eluent to give the title compound as a dark brown solid which had to be immediately stored in an amber vial because of its light sensitivity; 42 mg (71 %); mp >280 °C; IR (KBr) 3385, 3128, 3056, 1626, 1431, 1287; UV (MeOH) 340, 245, 230 nm (log E = 4.59, 4.59, 4.59); 'H NMR (DMSO-d6 + 3 drops of CF3COOH) 8 7.47-7.61 (m, 3H), 7.79-8.07 (m, 6H), 8.15-8.19 (m, 2H), 8.40 (d, 1 H, .l--9.0), 8.63 (s, 1 H), 8.67 (s, 1 H); '3C NMR (DMSO-d6 + 3 drops of CF3COOH) S 107.4, 111.7, 114.1, 114.6, 115.9, 116.3, 117.8, 122.3, 123.2, 125.5, 125.6, 126.6, 128.0, 129.2, 129.5, 131.9, 133.2, 134.7, 138.7, 139.8, 141.4, 147.1, 150.7, 154.3; HRMS (FAB) calcd for C26H,7N7 (MH+) 428.1624, found 428.1622.
The intermediate 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole was prepared as follows.
a. 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole.
A solution of 5-phenyl-2-[2'-(3,4-dinitrophenyl)benzimidazol-5'yl]benz-imidazole (75 mg, 0.16 mmol) in ethyl acetate (50 mL) was reduced by hydrogenation over 10% Pd/C ( 15 mg) for 90 minutes. The resulting solution was passed through a bed of Celite and the ethyl acetate was removed to give the diamine 1, which was used without further purification.
The starting 5-phenyl-2-[2'-(3,4-dinitrophenyl)benzimidazol-5'yl]benz-imidazole can be prepared as described by J.S. Kim et al. J.
Med. Chem. 1997, 40, 2818-2824.
Examyle.2. S-Phenyl-2'-(quinoxaline-6-yl~bibenzimidazole (3).
Diamine 1 (55 mg, 0.13 mmol) was dissolved in water (4 mL) and heated to 70 °C. Glyoxal2NaHS03 (50 mg, 0.13 mmol) was dissolved in hot water (80 °C, 3 mL) and added to the diamine slowly { as described by Jones, R.
G.; McLaughlin, K. C. 2,3-Pyrazinedicarboxylic acid. Org. synth. 1950, 30, 86).
After 15 minutes, the reaction mixture was cooled to room temperature and NazC03 was added. Extraction with ether followed by chromatographic separation with 10% methanol:ethyl acetate as the eluent gave the title compound as a yellow solid; 38 mg (67%); mp 235 °C; IR (KBr) 3385, 3169, 1624, 1554, 1431, 1297; UV (MeOH) 360, 255, 220 nm (log a = 4.52, 4.65, 4.59); 'H NMR (DMSO-d6 + 3 drops of CF3COOH) 8 7.46-7.61 (m, 3H), 7.80 (d, 2H, J--8.0), 7.89-8.26 (m, SH), 8.36 (d, 1H, J--9.0), 8.69-8.78 (m, 2H), 9.04-9.10 (m, 3H); '3C NMR (DMSO-d6 + 3 drops of CF3COOH) 8 111.7, 114.6, 116.5, 116.6, 117.9, 123.5, 123.9, 125.6, 127.5, 128.1, 128.2, 128.3, 128.6, 130.6, 131.6, 132.9, 138.9, 139.1, 139.7, 142.5, 143.7, 143.8, 147.3, 150.5, 153.1; HRMS (FAB) calcd for C2gH~9N6 (MH+) 439.1671, found 439.1677.
E~cam~. 5-Phenyl-2'-(quinoxalinedione-6-yl) bibenzimidazole (4).
Diamine 1 (40 mg, 0.096 mmol) and oxalic acid (20 mg, 0.22 mmol) in 4 N HCl were refluxed overnight (as described by Ohmori, J. Et al, J. Med Chem. 1996, 39, 1331-1338). Upon standing at room temperature, the title compound precipitated from the reaction mixture as a brownish solid; 15 mg (33%); mp > 280 °C; IR (KBr) 3339, 3217, 2845, 1623, 1578, 1506, 1469, 1272;
'H NMR (DMSO-d6) b 6.96 (d, 1H, J--9.0), 7.41-7.60 (m, 4H), 7.77-8.00 (m, 7H), 8.32 (d, IH,.I=9.0), 8.57 (s, 1H);'3C NMR (DMSO-d6+ 3 drops of CF3COOH) 8 106.5, 107.4, 111.7, 114.1, 114.7, 115.2, 116.7, 119.5, 122.3, 124.7, 125.7, 127.5, 128.2, 129.4, 131.9, 133.2, 138.8, 139.7, 139.8, 149.7, 152.7, 158.2; HRMS (FAB) calcd for C28H,9N6O2 {MH+) 471.1569, found 471.1584.
F.xamnle 4. The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.
( 'Compound X' 100.0 1 S Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose92.5 Magnesium stearate 300.0 (u1 T~ ablet 2 mgLtablet 'Compound X' 20.0 Microcrystalline cellulose410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5~
500.0 (~L),~ysule 'Compound X' 10.0 Colloidal silicon dioxide1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 600.0 (iv)~gection 1 ~,l~g mll mgLml 'Compound X' (free acid form) 1.0 Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL
(ya~leect~ ion 2 (, m /mllmg(m1 'Compound X' (free acid form)10.0 Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1 Polyethylene glycol 400 200.0 O1 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL
(~--A~.~1 I S 'Compound X' 20.0 Oleic acid 10.0 Trichloromonofluoromethane 5,000.0 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane 5,000.0 The above formulations may be obtained by conventional procedures well lrnown in the pharmaceutical art.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Ba , gromd of the Invention DNA-topoisomerases are enzymes present in the nuclei of cells where they catalyze the breaking and rejoining of DNA strands, controlling the topological state of DNA. Recent studies also suggest that topoisomerases are involved in regulating template supercoiling during RNA transcription. There are two major classes of mammalian topoisomerases. DNA-topoisomerase-I
catalyzes changes in the topological state of duplex DNA by performing transient single-strand breakage-union cycles. In contrast, mammalian topoisomerase II alters the topology of DNA by causing a transient enzyme bridged double-strand break, followed by strand passing and resealing.
Mammalian topoisomerase II has been further classified as Type II a and Type II
(3. The antitumor activity associated with agents which are topoisomerase poisons is associated with their ability to stabilize the enzyme-DNA cleavable complex. This drug-induced stabilization of the enzyme-DNA cleavable complex effectively converts the enzyme into a cellular poison.
Several antitumor agents in clinical use have potent activity as mammalian topoisomerase II poisons. These include adriamycin, actinomycin D, daunomycin, VP-16, and VM-26 (teniposide or epipodophyllotoxin).
In contrast to the number of clinical and experimental drugs which act as topoisomerase II poisons, there are currently only a limited number of agents which have been identified as topoisomerase I poisons. Camptothecin and its structurally-related analogs are among the most extensively studied topoisomerase I poisons. Recently, bi- and terbenzimidazoles (Chen et al., Cancer Res. 1993, 53, 1332-1335; Sun et al., J. Med. Chem. 1995, 38, 3638-3644; Kim et al., J. Med. Chem. 1996, 39, 992-998), certain benzo[c]phenanthridine and protoberberine alkaloids and their synthetic analogs (Makhey et al., Med. Chem. Res. 1995, S, 1-12; Janin et al., J. Med. Chem 1975, 18, 708-713; Makhey et al., Bioorg. & Med Chem. 1996, 4, 781-791), as well as the fungal metabolites, bulgarein (Fujii et al., J. Biol. Chem. 1993, 268, 131b0-13165) and saintopin (Yamashita et al., Biochemistry 1991, 30, 5838-5845) and indolocarbazoles (Yamashita et al., Biochemistry 1992, 31, 12069-12075) have been identified as topoisomerase I poisons.
Presently, a need exists for novel anti-cancer agents, for anti-cancer agents that exhibit improved activity, and for anti-cancer agents that exhibit fewer side-effects or improved selectivity compared to existing agents.
The present invention provides compounds that exhibit inhibitory activity against topoisomerase I, and compounds that are effective cytotoxic agents against cancer cells, including drug-resistant cancer cells.
Accordingly there is provided a compound of the invention which is a compound of formula I:
(I) wherein R, and R2 are each independently hydrogen, (C,-C6)alkyl, (C3-C~cycloalkyl, (C,-C~alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, halo, (C3-C~cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ
C6)alkanoyloxy, aryl or heteroaryl; or R, and RZ taken together are methylenedioxy; or R, and RZ taken together are benzo; wherein any aryl, heteroaryl, or benzo may optionally be substituted by l, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-Cbkycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyioxy, and halo;
R3 is hydrogen, (C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyloxy, or halo; and R4 and RS taken together are a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo;
wherein each X is independently absent or is H, O, (C,-C4)alkyl, phenyl or benzyl; and wherein at least one (e.g. 1 or 2) of said chain members is an N-H
group;
or a pharmaceutically acceptable salt thereof;
provided R4 and Rs taken together are not -N(H)-C(H~N-.
Preferrably, any carbon of R4 and R3 is saturated (-CHZ-) or unsaturated (=CH-).
The invention also provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
The invention also provides a therapeutic method comprising inhibiting cancer cells by administering to a mammal (e.g. a human) in need of such therapy, an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective to inhibit said cancer cells.
The invention also provides a method comprising inhibiting cancer cells by contacting said cancer cells in vitro or in vivo with an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective to inhibit said cancer cells, i.e. to inhibit their activity, such as their ability to divide, migrate, or proliferate.
The invention also provides a compound of formula I for use in medical therapy (preferably for use in treating cancer, e.g. solid tumors), as well as the use of a compound of formula I for the manufacture of a medicament useful for the treatment of cancer, e.g. solid tumors.
The invention also provides processes and novel intermediates disclosed herein which are useful for preparing compounds of the invention.
Some of the compounds of formula I are useful to prepare other compounds of formula I.
FIG. 1 Illustrates the synthesis of compounds of the invention (2 and 3) and the synthesis of compound 4.
FIG. 2 Shows the structure of compound 5.
The following definitions are used, unless otherwise described:
halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl"
embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, {C,-C,)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a bent-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymoiphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine topoisomerase poisoning activity or cytotoxic activity using the standard tests described herein, or using other similar tests which are well known in the art.
Specific and preferred values listed below 'for radicals, substituents, and ranges; are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents Specifically, (C,-C6)alkyl can be methyl, ethyl, propyl; isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C3-C6)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; (C3 C6)cycloalkyl(C,-C6)alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl; (C,-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy;(C,-C6)alkanoyl can be acetyl, propanoyl or butanoyl; halo(C,-C6)alkyl can be iodomethyl, bromomethyl, chloromethyl, fluoromethyl, trifluoromethyl, 2-chloroethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, or pentafluoroethyl;
hydroxy(C,-Cb)alkyl can be hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6-hydroxyhexyl; (C,-C6)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexyloxycarbonyl; {C,-C6)alkylthio can be methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, pentylthio, or hexylthio; (C2-C6)alkanoyloxy can be acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy; aryl can be phenyl, indenyl, or naphthyl; and heteroaryl can be furyl, imidazoiyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N
oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N
oxide) or quinolyl (or its N-oxide).
A specific value for R, is hydrogen, halo, aryl or heteroaryl;
wherein any aryl or hetemaryl may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-C6}cycloalkyl, (C,-Cb)alkoxy, nitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, and halo.
A specific value for R~ is hydrogen, halo, aryl or heteroaryl;
wherein any aryl or heteroaryl may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of {C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ C6)alkanoyloxy, and halo.
Specifically, R, and R2 taken together can be methylenedioxy.
Specifically, R, and RZ taken together can be benzo, which benzo may optionally be substituted by 1, 2, or 3 substituents independently selected from the group consisting of (C,-C6)alkyl, (C3-C6)cycloalkyl, (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C,-C6)alkyl, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ C6)alkanoyloxy, and halo.
A specific value for R3 is hydrogen. Another specific value for R3 is (C,-C6)alkoxy, vitro, hydroxy, halo(C,-C6)alkyl, trifluoromethoxy, (C,-C6)alkanoyl, hydroxy(C,-C6)alkyl, (C,-C6)alkoxycarbonyl, (C,-C6)alkylthio, (CZ-C6)alkanoyloxy, or halo.
Specifically, R4 and RS taken together can be -N(H)-N=N-, -N(H)-N(H)-CHZ-, -N(H)-N(H)-CH2-CHI-, -N(H)-CHZ-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-CHZ-, -N(H)-CHZ CHZ-N(H)-, -N(H)-CH,-CH2-O-, -N(H)-CHZ-CHZ S-, -N(H)-CHZ-CHZ-CH2-N(H)-, -N(H)-CH2-CHZ-CHI-O-, -N(H)-CHI-CHZ-CHZ-S-, -N(H)-CHZ-CH2-N(H)-CHZ-, -N(H)-CH2-CHZ-O-CHZ , -N(H)-CHZ-CHZ S-CHZ , -N(H)-C(=O)-C(-0)-CHZ-, -N(H)-C(-0)-C(-0)-N(H)-, -N(H)-C(-0)-C(~)-O-, -N(H)-C(=O)-C(=O)-S-, -N(H)-C(=O)-CHz-CHi , -N(H)-CHZ-N(H)-C(~)-, -CHZ-S-CHZ-N(H)-, -CHZ-N(H)-CHZ-S-, -CHz N(H)-CHZ , -CHZ-CHZ-N(H)-CHZ , -CHZ-CHZ CHZ-N(H)-CHz-, -CHZ-N(H)-CHZ-CHZ-O-, or -CHZ-N(H)-CHZ-CHZ-S-.
More specifically, R4 'and Rs taken together can be -N(H)-N=N-, -N(H)-CHZ-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHZ-, -N(H)-CHZ-CHZ-CHZ-, -N(H)-CHZ-CH2 CHZ-CHZ-, -N(H)-CHZ-CHZ-N(H)-, -N(H)-CHZ CHZ-O-, -N(H)-CHZ-CHZ-S-, -N(H)-CH2-CHZ-CHZ-N(H)-, -N(H)-CHZ-CHZ-CHZ-O-, -N(H)-CHZ CHZ-CHZ-S-, or -N(H)-C(=O)-C(~)-N(H)-.
Preferably, R4 and RS taken together are -N(H)-N=N-, -N(H)-C(=O)-C{=O)-N(H)-, -N(H)-CH=CH-, -N(H)-CHZ-CHz-, -N(H)-CHZ-CH; CHz-, or -N(H)-CHz-CHZ-N(H)-. More preferably, R4 and RS
taken together are -N(H)-N=N- or -N(H)-C(=O)-C(=O)-N(H)-.
A preferred group of compounds of formula I are compounds wherein R, and RZ are not both hydrogen.
Another preferred group of compounds of formula I are compounds wherein R, and RZ are each independently halo (e.g. bromo).
A preferred compound of formula I is a compound of formula III:
Rz ~ I N / ~ N
R~ N
N ~I
(III) wherein R,-R5 have any of the values defined herein for a compound of formula I.
Processes for preparing compounds of formula I are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified.
A compound of formula I wherein R4 and R5 taken together are -N(H)-N=N- can be prepared from a corresponding intermediate of formula II
(II) by treatment with NaNOz under acidic conditions. Suitable conditions for performing such a transformation are described in Example 1.
A compound of formula I wherein R4 and Rs taken together are -N{H)-C(=O)-C(=O)-N(H)- can be prepared from a corresponding compound of WO 99/3382.1 PCTNS98/27822 formula II by treatment with oxalic acid under acidic conditions. Suitable conditions for performing such a transformation are described in Example 2.
An intermediate useful for preparing a compound of formula I is an intermediate of formula II.
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion;
for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be made.
The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1 % of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin;
excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fivctose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage foam. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac ar sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage foam should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition; the active compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance 5 of the required particle size in the case of dispersions or by the use of surfactants.
The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride.
10 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, aleohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art;
for example, see Jacquet et al. (IJ.S. Pat. No. 4,608,392), Geria (U.S. Pat. No.
4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No.
4,820,508).
Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models.
Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compounds) of formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt%.
The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mglkg/day.
The compound is conveniently administered in unit dosage form;
for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about WO 99/33824 PC'f/US98/27822 75 pM, preferably, about 1 to 50 pM, most preferably, about 2 to about 30 ~M.
This may be achieved, for example, by the intravenous injection of a 0.05 to 5%
solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
The ability of a compound of the invention to effect topoisomerase I mediated DNA cleavage can be determined using pharmacological models that are well known to the art, for example, using a model like Test A described below.
Test A. Topoisomerase I cleavage assay.
Representative compounds of the invention were evaluated in a cleavage assay using recombinant topoisomerases I. This assay was preformed as described by B. Gatto et al. Cancer Res., 1996, 56, 2795-2800. Human topoisomerase I was isolated as a recombinant fusion protein using a T7 expression system. Plasmid YEpG was purified by the alkali lysis method followed by phenol deproteination and CsCI/ethidium isopycnic centrifugation as described by Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning, a Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY
1982; pp 149-185. The end-labeling of the plasmid was accomplished by digestion with a restriction enzyme followed by end-filling with Klenow polymerase as previously described by Liu, L. F.; Rowe, T. C.; Yang, L.;
Tewey, K. M.; Chen, G. L. "Cleavage of DNA by mammalian topoisomerase II," J. Biol.
Chem. 1983,158, 15365. ICso values were calculated after 4 days of continuous drug exposure. Topoisomerase I cleavage values are reported as REC, Relative Effective Concentration (i.e., concentrations relative to compound 5, whose value is arbitrarily assumed as 1) that is able to produce the same cleavage on the plasmid DNA in the presence of human topoisomerase I.
The cytotoxic effects of a compound of the invention can be determined using pharmacological models that are well known to the art, for example, using a model like Test B described below.
Test B. Cytotoxicity assay.
Cytotoxicity was determined using the MTT-microtiter plate tetrazolinium cytotoxicity assay (MTA) (See Chen A.Y. et al. Cancer Res. 1993, 53, 1332; Mosmann, T. J., J. Immunol. Methods 1983, 65, 55; and Carmichael, J.
et al. Cancer Res. 1987, 47, 936). The human lymphoblast RPMI 8402 and its camptothecin-resistant variant cell line, CPT-KS were provided by Dr. Toshiwo Andoh (Aachi Cancer Center Research Institute, Nagoya, Japan) (see Andoh, T.;
Okada, K. "Drug resistance mechanisms of topoisomerase I drugs," Adv. in Pharmacology 1994, 29B, 93. The cytotoxicity assay was performed using 96-well microtiter plates. Cells were grown in suspension at 37 °C in 5%
COZ and maintained by regular passage in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (0.1 mg/mL). For determination of ICso, cells were exposed continuously with varying concentrations of drug and MTT assays were performed at the end of the fourth day.
Data from Test A and Test B is shown in Table 1 for representative compounds of the invention.
Table 1. Pharmacological Activity of Compounds of the Invention Cytotoxicity ICso (pM) Compound DNA clea a RPMI CPT-KS
a 5 1 0.09 0.70 2 1 0.47 _ 0.47 3 1 2.3 21 4 - 20 >20 Topo I-mediated b Compounds of formula I are potent topoisomerase I poisons.
Additionally, compounds of formula I exhibit cytotoxic activity against RPMI
8402 cancer cells and camptothecin resistant CPT-KS cells. Accordingly, compounds of formula I are useful as cytotoxic agents, for the treatment of S cancers, and in particular, solid mammalian tumors or hematologic malignancies.
Compounds of the invention are also useful as pharmacological tools for in vitro and in vivo study of topoisomerase function and activity.
Comparison of the data for compounds 2 and 3 with the data for compound 4 suggests that topoisomerase poisoning activity and cytotoxic activity improve when R4 and RS taken together are a chain comprising a H
bonding functionality (e.g. N-H). Thus, the invention provides compounds of formula I wherein R4 and Rs taken together are a chain that comprises at least one N-H group.
As used herein, the term "solid mammalian tumors" includes cancers 1 S of the head and neck, lung, mesothelioma, mediastinum, esophagus, stomach, pancreas, hepatobiliary system, small intestine, colon, rectum, anus, kidney, ureter, bladder, prostate, urethra, penis, testis, gynecological organs, ovarian, breast, endocrine system, skin central nervous system; sarcomas of the soft tissue and bone; and melanoma of cutaneous and intraocular origin. The term "hematological malignancies" includes childhood leukemia and lymphomas, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia, plasma cell neoplasm and cancers associated with AIDS. The preferred mammalian species for treatment are humans and domesticated animals.
2S The invention will now be illustrated by the following non-limiting Examples, wherein unless otherwise stated: melting points were determined with a Thomas-Hoover Unimelt capillary melting point apparatus; column chromatography refers to hash chromatography conducted on SiliTech 32-63 pm, (ICN Biomedicals, Eschwegge, Ger.) using the solvent systems indicated;
infrared spectral data (IR) were obtained on a Perkin-Elmer 1600 Fourier transform spectrophotometer and are reported in cm''; proton ('H NMR) and carbon (~;C NMR) nuclear magnetic resonance were recorded on a Varian Gemini-200 Fourier Transform spectrometer; NMR spectra (200 MHZ ~H and SO
WO 99/33824 PCT/US98/Z7$22 MHZ'3C) were recorded in the deuterated solvent indicated with chemical shifts reported in 8 units downfield from tetramethylsilane (TMS); coupling constants are reported in hertz (Hz); mass spectra were obtained from Washington University Resource for Biomedical and Bio-organic Mass Spectrometry within 5 the Department of Chemistry at Washington University, St. Louis, MO; and combustion analyses were performed by Atlantic Microlabs, Inc., Norcross, GA, and were within t 0.4% of the theoretical value.
Fxarn lie 1__ 5-Phenyl-2'-(benzotriazol-5-yl)-bibenzimidazole (2).
10 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole (1), (58 mg, 0.14 mmol) was dissolved in O.IN HCI. This solution was placed in an ice bath and while maintaining a reaction temperature below 10 ° C. NaNOz ( 10.2 mg) in 5 mL water was added dropwise. The reaction mixture was stirred for I S minutes, neutralized with O.1N KOH, 15 extracted with ethyl acetate, and the resulting material was purified by chromatography, with 10% methanol:ethyl acetate as the eluent to give the title compound as a dark brown solid which had to be immediately stored in an amber vial because of its light sensitivity; 42 mg (71 %); mp >280 °C; IR (KBr) 3385, 3128, 3056, 1626, 1431, 1287; UV (MeOH) 340, 245, 230 nm (log E = 4.59, 4.59, 4.59); 'H NMR (DMSO-d6 + 3 drops of CF3COOH) 8 7.47-7.61 (m, 3H), 7.79-8.07 (m, 6H), 8.15-8.19 (m, 2H), 8.40 (d, 1 H, .l--9.0), 8.63 (s, 1 H), 8.67 (s, 1 H); '3C NMR (DMSO-d6 + 3 drops of CF3COOH) S 107.4, 111.7, 114.1, 114.6, 115.9, 116.3, 117.8, 122.3, 123.2, 125.5, 125.6, 126.6, 128.0, 129.2, 129.5, 131.9, 133.2, 134.7, 138.7, 139.8, 141.4, 147.1, 150.7, 154.3; HRMS (FAB) calcd for C26H,7N7 (MH+) 428.1624, found 428.1622.
The intermediate 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole was prepared as follows.
a. 5-Phenyl-2-[2'-(3,4-aminophenyl)benzimidazol-5'yl]benzimidazole.
A solution of 5-phenyl-2-[2'-(3,4-dinitrophenyl)benzimidazol-5'yl]benz-imidazole (75 mg, 0.16 mmol) in ethyl acetate (50 mL) was reduced by hydrogenation over 10% Pd/C ( 15 mg) for 90 minutes. The resulting solution was passed through a bed of Celite and the ethyl acetate was removed to give the diamine 1, which was used without further purification.
The starting 5-phenyl-2-[2'-(3,4-dinitrophenyl)benzimidazol-5'yl]benz-imidazole can be prepared as described by J.S. Kim et al. J.
Med. Chem. 1997, 40, 2818-2824.
Examyle.2. S-Phenyl-2'-(quinoxaline-6-yl~bibenzimidazole (3).
Diamine 1 (55 mg, 0.13 mmol) was dissolved in water (4 mL) and heated to 70 °C. Glyoxal2NaHS03 (50 mg, 0.13 mmol) was dissolved in hot water (80 °C, 3 mL) and added to the diamine slowly { as described by Jones, R.
G.; McLaughlin, K. C. 2,3-Pyrazinedicarboxylic acid. Org. synth. 1950, 30, 86).
After 15 minutes, the reaction mixture was cooled to room temperature and NazC03 was added. Extraction with ether followed by chromatographic separation with 10% methanol:ethyl acetate as the eluent gave the title compound as a yellow solid; 38 mg (67%); mp 235 °C; IR (KBr) 3385, 3169, 1624, 1554, 1431, 1297; UV (MeOH) 360, 255, 220 nm (log a = 4.52, 4.65, 4.59); 'H NMR (DMSO-d6 + 3 drops of CF3COOH) 8 7.46-7.61 (m, 3H), 7.80 (d, 2H, J--8.0), 7.89-8.26 (m, SH), 8.36 (d, 1H, J--9.0), 8.69-8.78 (m, 2H), 9.04-9.10 (m, 3H); '3C NMR (DMSO-d6 + 3 drops of CF3COOH) 8 111.7, 114.6, 116.5, 116.6, 117.9, 123.5, 123.9, 125.6, 127.5, 128.1, 128.2, 128.3, 128.6, 130.6, 131.6, 132.9, 138.9, 139.1, 139.7, 142.5, 143.7, 143.8, 147.3, 150.5, 153.1; HRMS (FAB) calcd for C2gH~9N6 (MH+) 439.1671, found 439.1677.
E~cam~. 5-Phenyl-2'-(quinoxalinedione-6-yl) bibenzimidazole (4).
Diamine 1 (40 mg, 0.096 mmol) and oxalic acid (20 mg, 0.22 mmol) in 4 N HCl were refluxed overnight (as described by Ohmori, J. Et al, J. Med Chem. 1996, 39, 1331-1338). Upon standing at room temperature, the title compound precipitated from the reaction mixture as a brownish solid; 15 mg (33%); mp > 280 °C; IR (KBr) 3339, 3217, 2845, 1623, 1578, 1506, 1469, 1272;
'H NMR (DMSO-d6) b 6.96 (d, 1H, J--9.0), 7.41-7.60 (m, 4H), 7.77-8.00 (m, 7H), 8.32 (d, IH,.I=9.0), 8.57 (s, 1H);'3C NMR (DMSO-d6+ 3 drops of CF3COOH) 8 106.5, 107.4, 111.7, 114.1, 114.7, 115.2, 116.7, 119.5, 122.3, 124.7, 125.7, 127.5, 128.2, 129.4, 131.9, 133.2, 138.8, 139.7, 139.8, 149.7, 152.7, 158.2; HRMS (FAB) calcd for C28H,9N6O2 {MH+) 471.1569, found 471.1584.
F.xamnle 4. The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.
( 'Compound X' 100.0 1 S Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose92.5 Magnesium stearate 300.0 (u1 T~ ablet 2 mgLtablet 'Compound X' 20.0 Microcrystalline cellulose410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5~
500.0 (~L),~ysule 'Compound X' 10.0 Colloidal silicon dioxide1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 600.0 (iv)~gection 1 ~,l~g mll mgLml 'Compound X' (free acid form) 1.0 Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL
(ya~leect~ ion 2 (, m /mllmg(m1 'Compound X' (free acid form)10.0 Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1 Polyethylene glycol 400 200.0 O1 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL
(~--A~.~1 I S 'Compound X' 20.0 Oleic acid 10.0 Trichloromonofluoromethane 5,000.0 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane 5,000.0 The above formulations may be obtained by conventional procedures well lrnown in the pharmaceutical art.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Claims (22)
1. A compound of formula I:
wherein R1 and R2 are each independently hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, halo, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, aryl or heteroaryl; or R1 and R2 taken together are methylenedioxy; or R1 and R2 taken together are benzo; wherein any aryl, heteroaryl, or benzo may optionally be substituted by 1, 2, or 3 substitutents independently selected from the group consisting of (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6) alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, and halo;
R3 is hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, or halo; and R4 and R5 taken together are a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo;
wherein each X is independently absent or is H, O, (C1-C4)alkyl, phenyl or benzyl; and wherein at least one (e.g. 1 or 2) of said chain members is an N-H
group; or a pharmaceutically acceptable salt thereof;
provided R4 and R5 taken together are not -N(H)-C(H)=N-.
wherein R1 and R2 are each independently hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, halo, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, aryl or heteroaryl; or R1 and R2 taken together are methylenedioxy; or R1 and R2 taken together are benzo; wherein any aryl, heteroaryl, or benzo may optionally be substituted by 1, 2, or 3 substitutents independently selected from the group consisting of (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6) alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, and halo;
R3 is hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, or halo; and R4 and R5 taken together are a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo;
wherein each X is independently absent or is H, O, (C1-C4)alkyl, phenyl or benzyl; and wherein at least one (e.g. 1 or 2) of said chain members is an N-H
group; or a pharmaceutically acceptable salt thereof;
provided R4 and R5 taken together are not -N(H)-C(H)=N-.
2. The compound of claim 1 wherein R1 is hydrogen, halo, aryl or heteroaryl; wherein any aryl or heteroaryl may optionally be substituted by 1, 2, or 3 substitutents independently selected from the group consisting of (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, and halo.
3. The compound of claim 1 wherein R2 is hydrogen, halo, aryl or heteroaryl; wherein any aryl or heteroaryl may optionally be substituted by 1, 2, or 3 substitutents independently selected from the group consisting of (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6) alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, and halo.
4. The compound of claim 1 wherein R1 and R2 taken together are methylenedioxy.
5. The compound of claim 1 wherein R1 and R2 taken together are benzo, which benzo is optionally substituted by 1, 2, or 3 substitutents independently selected from the group consisting of (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C3-C6)cycloalkyl(C1-C6)alkyl, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, and halo.
6. The compound of claim 1 wherein R3 is hydrogen.
7. The compound of claim 1 wherein R3 is (C1-C6)alkoxy, nitro, hydroxy, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, (C2-C6)alkanoyloxy, or halo.
8. The compound of claim 1 wherein R4 and R5 taken together are -N(H)-N=N-, -N(H)-N(H)-CH2-, -N(H)-N(H)-CH2-CH2-, -N(H)-CH2-N(H)-, -N(H)-CH=CH-, -N(H)-CH2-CH2-, -N(H)-CH2-CH2-CH2-, -N(H)-CH2-CH2-CH2-CH2-, -N(H)-CH2-CH2-N(H)-, -N(H)-CH2-CH2 O-, -N(H)-CH2-CH2-S-, -N(H)-CH2-CH2-CH2-N(H)-, -N(H)-CH2-CH2-CH2-O-, -N(H)-CH2-CH2-CH2-S-, -N(H)-CH2-CH2-N(H)-CH2-, -N(H)-CH2-CH2-O-CH2-, -N(H)-CH2-CH2-S-CH2-, -N(H)-C(=O)-C(=O)-CH2-, -N(H)-C(=O)-C(=O)-N(H)-, -N(H)-C(=O)-C(=O)-O-, -N(H)-C(=O)-C(=O)-S-, -N(H)-C(=O)-CH2-CH2-, -N(H)-CH2-N(H)-C(=O)-, -CH2-S-CH2-N(H)-, -CH2-N(H)-CH2-S-, -CH2-N(H)-CH2-, -CH2-CH2-N(H)-CH2-, -CH2-CH2-CH2-N(H)-CH2-, -CH2-N(H)-CH2-CH2-O-, or -CH2-N(H)-CH2-CH2-S-.
9. The compound of claim 1 wherein R4 and R5 taken together are -N(H)-N=N-, -N(H)-CH2-N(H)-, -N(H)-CH=CH-, -N(H)-CH2-CH2-, -N(H)-CH2-CH2-CH2-, -N(H)-CH2-CH2-CH2-CH2-, -N(H)-CH2-CH2-N(H)-, -N(H)-CH2-CH2-O-, -N(H)-CH2-CH2-S-, -N(H)-CH2-CH2-CH2-N(H)-, -N(H)-CH2-CH2-CH2-O-, -N(H)-CH2-CH2-CH2-S-, or -N(H)-C(=O)-C(=O)-N(H)-.
10. The compound of claim 1 wherein R4 and R5 taken together are -N(H)-N=N-, -N(H)-C(=O)-C(=O)-N(H)-, -N(H)-CH=CH-, -N(H)-CH2-CH2-, -N(H)-CH2-CH2-CH2-, or -N(H)-CH2-CH2-N(H)-.
11. The compound of claim 1 wherein R4 and R5 taken together are -N(H)-N=N- or -N(H)-C(=O)-C(=O)-N(H)-.
12. The compound of claim 1 wherein R1 and R2 are not both hydrogen.
13. The compound of claim 1 wherein R1 and R2 are each independently halo.
14. The compound of claim 1 wherein R1 and R2 are each bromo.
15. A pharmaceutical composition comprising a compound of any one of claims 1-14, in combination with a pharmaceutically acceptable diluent or carrier.
16. A therapeutic method comprising inhibiting cancer cells by administering to a mammal in need of such therapy, an amount of a compound of claim 1, effective to inhibit said cancer cells.
17. A method comprising inhibiting cancer cells by contacting said cancer cells with an effective amount of a compound of claim 1.
18. A compound of any one of claims 1-14 for use in medical therapy.
19. The compound of claim 18 wherein the medical therapy is treating cancer.
20. The compound of claim 19 wherein the cancer is a solid tumor.
21. The use of a compound of any one of claims 1-14 for the manufacture of a medicament useful for the treatment of cancer.
22. The use of claim 21 wherein the cancer is a solid tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/016,694 US6221425B1 (en) | 1998-01-30 | 1998-01-30 | Lubricious hydrophilic coating for an intracorporeal medical device |
US09/016,694 | 1998-01-30 | ||
PCT/US1999/001919 WO1999038546A1 (en) | 1998-01-30 | 1999-01-29 | Hydrophilic coating for an intracorporeal medical device |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2316223A1 true CA2316223A1 (en) | 1999-08-05 |
Family
ID=21778447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002316223A Abandoned CA2316223A1 (en) | 1998-01-30 | 1999-01-29 | Hydrophilic coating for an intracorporeal medical device |
Country Status (8)
Country | Link |
---|---|
US (3) | US6221425B1 (en) |
EP (1) | EP1051208B1 (en) |
JP (1) | JP2002501788A (en) |
AT (1) | ATE330646T1 (en) |
AU (2) | AU2019299A (en) |
CA (1) | CA2316223A1 (en) |
DE (1) | DE69932034T2 (en) |
WO (2) | WO1999038545A1 (en) |
Families Citing this family (340)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7282220B1 (en) * | 1996-11-05 | 2007-10-16 | Hsing-Wen Sung | Genipin-crosslinked gelatin microspheres as drug carrier |
ES2179646T3 (en) | 1998-04-27 | 2003-01-16 | Surmodics Inc | COATING THAT RELEASES A BIOACTIVE AGENT. |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US20040043068A1 (en) * | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US6955661B1 (en) | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US7947015B2 (en) * | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US8506519B2 (en) | 1999-02-16 | 2013-08-13 | Flowcardia, Inc. | Pre-shaped therapeutic catheter |
US6855123B2 (en) | 2002-08-02 | 2005-02-15 | Flow Cardia, Inc. | Therapeutic ultrasound system |
US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6358557B1 (en) * | 1999-09-10 | 2002-03-19 | Sts Biopolymers, Inc. | Graft polymerization of substrate surfaces |
US6458867B1 (en) | 1999-09-28 | 2002-10-01 | Scimed Life Systems, Inc. | Hydrophilic lubricant coatings for medical devices |
EP1104681A1 (en) * | 1999-12-03 | 2001-06-06 | Biomat B.V. | Wire, tube or catheter with hydrophilic coating |
JP5000826B2 (en) * | 2000-01-24 | 2012-08-15 | バイオコンパテイブルズ・ユーケイ・リミテツド | Coated implant |
SE0000363A0 (en) * | 2000-02-04 | 2001-08-05 | Zoucas Kirurgkonsult Ab | Coated medical device |
JP2003533468A (en) * | 2000-02-28 | 2003-11-11 | ゲル−デル テクノロジーズ,インコーポレイティド | Protein matrix materials, production and their production and use |
US7220276B1 (en) * | 2000-03-06 | 2007-05-22 | Surmodics, Inc. | Endovascular graft coatings |
AU2001247425A1 (en) | 2000-04-10 | 2001-10-23 | Advanced Cardiovascular Systems Inc. | Selectively coated stent delivery system and method of manufacture thereof |
US6673385B1 (en) | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US7682648B1 (en) | 2000-05-31 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for forming polymeric coatings on stents |
US6695817B1 (en) | 2000-07-11 | 2004-02-24 | Icu Medical, Inc. | Medical valve with positive flow characteristics |
US6451003B1 (en) * | 2000-08-16 | 2002-09-17 | Biolink Corporation | Method and apparatus for overcoming infection in a tissue pocket surrounding an implanted device |
US6706274B2 (en) * | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
ATE281849T1 (en) * | 2001-02-28 | 2004-11-15 | Uroteq Inc | METHOD FOR PRODUCING ANTIMICROBIAL POLYMER SURFACES |
US20020163504A1 (en) * | 2001-03-13 | 2002-11-07 | Pallakoff Matthew G. | Hand-held device that supports fast text typing |
DE10115740A1 (en) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
US20020161376A1 (en) * | 2001-04-27 | 2002-10-31 | Barry James J. | Method and system for delivery of coated implants |
US6673453B2 (en) * | 2001-06-12 | 2004-01-06 | Biocoat Incorporated | Coatings appropriate for medical devices |
US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
SE523216C2 (en) * | 2001-07-27 | 2004-04-06 | Zoucas Kirurgkonsult Ab | heparin stent |
US7682669B1 (en) * | 2001-07-30 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device |
CA2455923A1 (en) * | 2001-07-30 | 2003-10-09 | Sts Biopolymers, Inc. | Graft polymer matrices |
US7135189B2 (en) | 2001-08-23 | 2006-11-14 | Boston Scientific Scimed, Inc. | Compositions and techniques for localized therapy |
US20030060873A1 (en) * | 2001-09-19 | 2003-03-27 | Nanomedical Technologies, Inc. | Metallic structures incorporating bioactive materials and methods for creating the same |
US7776379B2 (en) * | 2001-09-19 | 2010-08-17 | Medlogics Device Corporation | Metallic structures incorporating bioactive materials and methods for creating the same |
EP1429689A4 (en) * | 2001-09-24 | 2006-03-08 | Medtronic Ave Inc | Rational drug therapy device and methods |
JP2005518827A (en) * | 2001-10-05 | 2005-06-30 | サーモディクス,インコーポレイテッド | Particle fixing coating and use thereof |
US20030077310A1 (en) * | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
US20040143180A1 (en) * | 2001-11-27 | 2004-07-22 | Sheng-Ping Zhong | Medical devices visible under magnetic resonance imaging |
US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
US20030109865A1 (en) * | 2001-12-12 | 2003-06-12 | Megadyne Medical Products, Inc. | Utilization of a multi-character material in a surface coating of an electrosurgical instrument |
FR2833961B1 (en) * | 2001-12-20 | 2004-04-02 | Virsol | PROCESS FOR THE PREPARATION OF CROSSLINKED POLY (ETHYLENE OXIDE) FILMS |
US7348055B2 (en) * | 2001-12-21 | 2008-03-25 | Surmodics, Inc. | Reagent and method for providing coatings on surfaces |
US20030118658A1 (en) * | 2001-12-21 | 2003-06-26 | Trogolo Jeffrey A. | High aspect ratio encapsulated inorganic antimicrobial additive for controlled release |
US7357949B2 (en) * | 2001-12-21 | 2008-04-15 | Agion Technologies Inc. | Encapsulated inorganic antimicrobial additive for controlled release |
US20050008839A1 (en) * | 2002-01-30 | 2005-01-13 | Cramer Ronald Dean | Method for hydrophilizing materials using hydrophilic polymeric materials with discrete charges |
US8728510B1 (en) * | 2002-03-15 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing a bioadhesive material |
US7387836B2 (en) * | 2002-04-17 | 2008-06-17 | Genzyme Corporation | Aziridine compounds and their use in medical devices |
US7008979B2 (en) * | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
US20040267355A1 (en) * | 2002-04-30 | 2004-12-30 | Neal Scott | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US7097850B2 (en) * | 2002-06-18 | 2006-08-29 | Surmodics, Inc. | Bioactive agent release coating and controlled humidity method |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
EP1521603B1 (en) * | 2002-07-12 | 2011-01-19 | Cook Incorporated | Coated medical device |
US8133236B2 (en) | 2006-11-07 | 2012-03-13 | Flowcardia, Inc. | Ultrasound catheter having protective feature against breakage |
US9955994B2 (en) | 2002-08-02 | 2018-05-01 | Flowcardia, Inc. | Ultrasound catheter having protective feature against breakage |
US7335180B2 (en) | 2003-11-24 | 2008-02-26 | Flowcardia, Inc. | Steerable ultrasound catheter |
US7604608B2 (en) | 2003-01-14 | 2009-10-20 | Flowcardia, Inc. | Ultrasound catheter and methods for making and using same |
US7220233B2 (en) | 2003-04-08 | 2007-05-22 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US7137963B2 (en) | 2002-08-26 | 2006-11-21 | Flowcardia, Inc. | Ultrasound catheter for disrupting blood vessel obstructions |
US6942677B2 (en) | 2003-02-26 | 2005-09-13 | Flowcardia, Inc. | Ultrasound catheter apparatus |
US20030039697A1 (en) * | 2002-09-12 | 2003-02-27 | Yi-Ju Zhao | Matrices containing nitric oxide donors and reducing agents and their use |
DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
US20060100695A1 (en) * | 2002-09-27 | 2006-05-11 | Peacock James C Iii | Implantable stent with modified ends |
US6770729B2 (en) * | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
WO2004043507A1 (en) * | 2002-11-07 | 2004-05-27 | Carbon Medical Technologies, Inc. | Biocompatible medical device coatings |
ES2420914T3 (en) | 2002-11-13 | 2013-08-27 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
CA2505801A1 (en) | 2002-11-13 | 2004-05-27 | Rosanne Crooke | Antisense modulation of apolipoprotein b expression |
US20040111144A1 (en) * | 2002-12-06 | 2004-06-10 | Lawin Laurie R. | Barriers for polymeric coatings |
US7758880B2 (en) | 2002-12-11 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible polyacrylate compositions for medical applications |
US7776926B1 (en) | 2002-12-11 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for implantable medical devices |
US7264859B2 (en) * | 2002-12-19 | 2007-09-04 | Kimberly-Clark Worldwide, Inc. | Lubricious coating for medical devices |
US7220491B2 (en) * | 2002-12-19 | 2007-05-22 | Kimberly-Clark Worldwide, Inc. | Lubricious coating for medical devices |
US7628859B1 (en) * | 2002-12-27 | 2009-12-08 | Advanced Cardiovascular Systems, Inc. | Mounting assembly for a stent and a method of using the same to coat a stent |
US20040236415A1 (en) * | 2003-01-02 | 2004-11-25 | Richard Thomas | Medical devices having drug releasing polymer reservoirs |
US20060135940A1 (en) * | 2003-01-06 | 2006-06-22 | The Trustees Of Columbia | Programmed pulsed infusion methods and devices |
US20060047261A1 (en) * | 2004-06-28 | 2006-03-02 | Shailendra Joshi | Intra-arterial catheter for drug delivery |
US6742952B1 (en) | 2003-02-28 | 2004-06-01 | Bic Corporation | Transparent or translucent tubular structure |
EP2918296A1 (en) | 2003-02-28 | 2015-09-16 | Biointeractions Ltd. | Polymeric network system for medical devices and methods of use |
JP4614630B2 (en) * | 2003-03-31 | 2011-01-19 | 有限会社筑波物質情報研究所 | Functional polymer compound and biosensor using the same |
US20050164951A1 (en) * | 2003-04-03 | 2005-07-28 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
AU2004228028B2 (en) * | 2003-04-03 | 2009-12-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
US20040243224A1 (en) * | 2003-04-03 | 2004-12-02 | Medtronic Vascular, Inc. | Methods and compositions for inhibiting narrowing in mammalian vascular pathways |
US7641643B2 (en) | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
US8821473B2 (en) | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US20040215313A1 (en) * | 2003-04-22 | 2004-10-28 | Peiwen Cheng | Stent with sandwich type coating |
AU2004237774B2 (en) | 2003-05-02 | 2009-09-10 | Surmodics, Inc. | Implantable controlled release bioactive agent delivery device |
US8246974B2 (en) | 2003-05-02 | 2012-08-21 | Surmodics, Inc. | Medical devices and methods for producing the same |
US6923996B2 (en) | 2003-05-06 | 2005-08-02 | Scimed Life Systems, Inc. | Processes for producing polymer coatings for release of therapeutic agent |
US7279174B2 (en) | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US8465537B2 (en) | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US7318945B2 (en) * | 2003-07-09 | 2008-01-15 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent having dipped layers |
US20050124896A1 (en) * | 2003-08-25 | 2005-06-09 | Jacob Richter | Method for protecting implantable sensors and protected implantable sensors |
DE60312326T2 (en) * | 2003-09-03 | 2007-11-08 | Research In Motion Ltd., Waterloo | Methods and apparatus for displaying a home network name |
US8021331B2 (en) * | 2003-09-15 | 2011-09-20 | Atrium Medical Corporation | Method of coating a folded medical device |
WO2005027994A2 (en) * | 2003-09-15 | 2005-03-31 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using a porous medical device |
EP1663343B8 (en) * | 2003-09-15 | 2019-12-04 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US7758510B2 (en) | 2003-09-19 | 2010-07-20 | Flowcardia, Inc. | Connector for securing ultrasound catheter to transducer |
US7953499B2 (en) * | 2003-09-30 | 2011-05-31 | Cardiac Pacemakers, Inc. | Drug-eluting electrode |
EP1675908B1 (en) * | 2003-10-07 | 2008-12-17 | Coloplast A/S | Composition useful as an adhesive ans use of such a composition |
US7208172B2 (en) * | 2003-11-03 | 2007-04-24 | Medlogics Device Corporation | Metallic composite coating for delivery of therapeutic agents from the surface of implantable devices |
CN1878579A (en) * | 2003-11-07 | 2006-12-13 | 拜克技术有限公司 | Method for preparing drug eluting medical devices and medical devices obtained therefrom |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
EP1687043A2 (en) * | 2003-11-20 | 2006-08-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
JP2007512102A (en) | 2003-11-20 | 2007-05-17 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン, インク. | Portable manual pump for fluid suction |
US20060085062A1 (en) * | 2003-11-28 | 2006-04-20 | Medlogics Device Corporation | Implantable stent with endothelialization factor |
US20050119723A1 (en) * | 2003-11-28 | 2005-06-02 | Medlogics Device Corporation | Medical device with porous surface containing bioerodable bioactive composites and related methods |
US20050149174A1 (en) * | 2003-12-18 | 2005-07-07 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050154455A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050154451A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050152942A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050152943A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
EP1696977A2 (en) * | 2003-12-23 | 2006-09-06 | Advanced Medical Optics, Inc. | Lubricious, biocompatible coatings for medical devices |
US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050154452A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
JP2007517550A (en) * | 2004-01-02 | 2007-07-05 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | Medical device coated with high density lipoprotein |
US20050159809A1 (en) * | 2004-01-21 | 2005-07-21 | Medtronic Vascular, Inc. | Implantable medical devices for treating or preventing restenosis |
US20050165452A1 (en) * | 2004-01-28 | 2005-07-28 | Medtronic, Inc. | Antithrombogenic medical device |
US7534495B2 (en) * | 2004-01-29 | 2009-05-19 | Boston Scientific Scimed, Inc. | Lubricious composition |
US20050197691A1 (en) * | 2004-02-18 | 2005-09-08 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US8137397B2 (en) * | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
WO2005097673A1 (en) * | 2004-03-30 | 2005-10-20 | Toyo Advanced Technologies Co., Ltd. | Method for treating surface of base, surface-treated base, material for medical use and instrument for medical use |
US8043631B2 (en) * | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
US8293890B2 (en) | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
EP1746943A1 (en) * | 2004-05-06 | 2007-01-31 | Boston Scientific Limited | Variable size retrieval basket |
US7758572B2 (en) * | 2004-05-20 | 2010-07-20 | Boston Scientific Scimed, Inc. | Medical devices and methods including cooling balloons having nanotubes |
US20050261762A1 (en) * | 2004-05-21 | 2005-11-24 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7563780B1 (en) | 2004-06-18 | 2009-07-21 | Advanced Cardiovascular Systems, Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US7595355B2 (en) * | 2004-06-24 | 2009-09-29 | Agion Technologies, Inc. | Antimicrobial coating for erosive environments |
US7494665B1 (en) | 2004-07-30 | 2009-02-24 | Advanced Cardiovascular Systems, Inc. | Polymers containing siloxane monomers |
US7540852B2 (en) | 2004-08-26 | 2009-06-02 | Flowcardia, Inc. | Ultrasound catheter devices and methods |
US20060062822A1 (en) * | 2004-09-21 | 2006-03-23 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US7776380B2 (en) * | 2004-09-22 | 2010-08-17 | Volcano Corporation | Method of making catheters with additives consolidated into polymer wall |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8858978B2 (en) | 2004-09-28 | 2014-10-14 | Atrium Medical Corporation | Heat cured gel and method of making |
US8337475B2 (en) | 2004-10-12 | 2012-12-25 | C. R. Bard, Inc. | Corporeal drainage system |
US20060083770A1 (en) * | 2004-10-15 | 2006-04-20 | Specialty Coating Systems, Inc. | Medical devices and methods of preparation and use |
US7662910B2 (en) | 2004-10-20 | 2010-02-16 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
US20060088571A1 (en) * | 2004-10-21 | 2006-04-27 | Medtronic Vascular, Inc. | Biocompatible and hemocompatible polymer compositions |
US8603634B2 (en) | 2004-10-27 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
ATE542564T1 (en) | 2004-11-05 | 2012-02-15 | Icu Medical Inc | MEDICAL CONNECTOR WITH HIGH FLOW CHARACTERISTICS |
WO2006056482A1 (en) | 2004-11-29 | 2006-06-01 | Dsm Ip Assets B.V. | Method for reducing the amount of migrateables of polymer coatings |
US8874204B2 (en) | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7604818B2 (en) | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US8221343B2 (en) | 2005-01-20 | 2012-07-17 | Flowcardia, Inc. | Vibrational catheter devices and methods for making same |
EP1853328A2 (en) * | 2005-02-23 | 2007-11-14 | SurModics, Inc. | Implantable medical articles having laminin coatings and methods of use |
US7527604B2 (en) * | 2005-03-09 | 2009-05-05 | Boston Scientific Scimed, Inc. | Rotatable multi-port therapeutic delivery device |
US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
JP2008541950A (en) * | 2005-06-02 | 2008-11-27 | サーモディクス,インコーポレイティド | Hydrophilic polymer coating for medical products |
US20060282114A1 (en) * | 2005-06-09 | 2006-12-14 | Medtronic Vascular, Inc. | Embolic protection apparatus with vasodilator coating |
DE102005033520B4 (en) * | 2005-07-14 | 2007-12-20 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Preparation, in particular cosmetic preparation, process for their preparation and their use |
AU2006270221B2 (en) | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US11147902B2 (en) * | 2005-07-20 | 2021-10-19 | Surmodics, Inc. | Polymeric coatings and methods for cell attachment |
US20070027530A1 (en) * | 2005-07-26 | 2007-02-01 | Medtronic Vascular, Inc. | Intraluminal device, catheter assembly, and method of use thereof |
BRPI0503201B8 (en) * | 2005-07-28 | 2021-05-25 | Sci Tech Produtos Medicos Ltda | stents coated with hydrophilic polymer blends, eluting nitric oxide and s-nitrosothiols |
US9101949B2 (en) | 2005-08-04 | 2015-08-11 | Eilaz Babaev | Ultrasonic atomization and/or seperation system |
US7896539B2 (en) | 2005-08-16 | 2011-03-01 | Bacoustics, Llc | Ultrasound apparatus and methods for mixing liquids and coating stents |
WO2007024649A2 (en) * | 2005-08-19 | 2007-03-01 | X-Cell Medical Incorporated | Methods of treating and preventing acute myocardial infarction |
US8343473B2 (en) | 2005-08-24 | 2013-01-01 | Purdue Research Foundation | Hydrophilized antimicrobial polymers |
US20070048249A1 (en) | 2005-08-24 | 2007-03-01 | Purdue Research Foundation | Hydrophilized bactericidal polymers |
US20070067020A1 (en) * | 2005-09-22 | 2007-03-22 | Medtronic Vasular, Inc. | Intraluminal stent, delivery system, and a method of treating a vascular condition |
US8177772B2 (en) | 2005-09-26 | 2012-05-15 | C. R. Bard, Inc. | Catheter connection systems |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
DK1957130T3 (en) * | 2005-12-09 | 2010-11-22 | Dsm Ip Assets Bv | Hydrophilic coating comprising a polyelectrolyte |
US20070148390A1 (en) * | 2005-12-27 | 2007-06-28 | Specialty Coating Systems, Inc. | Fluorinated coatings |
ES2612188T3 (en) | 2006-02-01 | 2017-05-12 | Hollister Incorporated | Methods of applying a hydrophilic coating to a substrate and substrates having a hydrophilic coating |
TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
US20070231361A1 (en) * | 2006-03-28 | 2007-10-04 | Medtronic Vascular, Inc. | Use of Fatty Acids to Inhibit the Growth of Aneurysms |
US9282984B2 (en) | 2006-04-05 | 2016-03-15 | Flowcardia, Inc. | Therapeutic ultrasound system |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US7732190B2 (en) | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US20080057298A1 (en) * | 2006-08-29 | 2008-03-06 | Surmodics, Inc. | Low friction particulate coatings |
WO2008031601A1 (en) * | 2006-09-13 | 2008-03-20 | Dsm Ip Assets B.V. | Antimicrobial hydrophilic coating comprising metallic silver particles |
EP2059272B1 (en) * | 2006-09-13 | 2018-02-28 | DSM IP Assets B.V. | Coating formulation for medical coating |
WO2008052140A2 (en) | 2006-10-25 | 2008-05-02 | Icu Medical, Inc. | Medical connector |
US8246643B2 (en) | 2006-11-07 | 2012-08-21 | Flowcardia, Inc. | Ultrasound catheter having improved distal end |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
US20080140022A1 (en) * | 2006-12-08 | 2008-06-12 | Warsaw Orthopedic, Inc. | Coated Cannula with Protective Tip for Insertion Into a Patient |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
US8273402B2 (en) * | 2007-02-26 | 2012-09-25 | Medtronic Vascular, Inc. | Drug coated stent with magnesium topcoat |
ES2387699T3 (en) * | 2007-02-28 | 2012-09-28 | Dsm Ip Assets B.V. | Hydrophilic coating |
JP5587612B2 (en) * | 2007-02-28 | 2014-09-10 | ディーエスエム アイピー アセッツ ビー.ブイ. | Hydrophilic coating |
US20080294237A1 (en) * | 2007-04-04 | 2008-11-27 | Jack Fa-De Chu | Inflatable devices and methods to protect aneurysmal wall |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
US7780095B2 (en) | 2007-07-13 | 2010-08-24 | Bacoustics, Llc | Ultrasound pumping apparatus |
US7753285B2 (en) | 2007-07-13 | 2010-07-13 | Bacoustics, Llc | Echoing ultrasound atomization and/or mixing system |
US8617114B2 (en) * | 2007-07-13 | 2013-12-31 | Abbott Cardiovascular Systems Inc. | Drug coated balloon catheter |
US8690823B2 (en) * | 2007-07-13 | 2014-04-08 | Abbott Cardiovascular Systems Inc. | Drug coated balloon catheter |
US8128599B2 (en) * | 2007-07-20 | 2012-03-06 | Tyco Healthcare Group Lp | Lubricious coatings |
WO2009020960A1 (en) | 2007-08-06 | 2009-02-12 | The Regents Of The University Of California | Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
US20090041923A1 (en) * | 2007-08-06 | 2009-02-12 | Abbott Cardiovascular Systems Inc. | Medical device having a lubricious coating with a hydrophilic compound in an interlocking network |
CA2599082A1 (en) * | 2007-08-27 | 2009-02-27 | Ping I. Lee | Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds |
US8445217B2 (en) | 2007-09-20 | 2013-05-21 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US8216629B2 (en) * | 2007-10-29 | 2012-07-10 | Advanced Vision Science, Inc. | Lubricious intraocular lens insertion device |
US8361052B2 (en) | 2007-10-30 | 2013-01-29 | Uti Limited Partnership | Method and system for sustained-release of sclerosing agent |
US8512731B2 (en) * | 2007-11-13 | 2013-08-20 | Medtronic Minimed, Inc. | Antimicrobial coatings for medical devices and methods for making and using them |
DE102007055692A1 (en) * | 2007-12-03 | 2009-06-04 | Wacker Chemie Ag | Radically crosslinkable polymer compositions containing epoxy-functional copolymers |
WO2009076372A2 (en) | 2007-12-10 | 2009-06-18 | Molecular Sensing, Inc. | Temperature-stable interferometer |
US20090157047A1 (en) * | 2007-12-13 | 2009-06-18 | Boston Scientific Scimed, Inc. | Medical device coatings and methods of forming such coatings |
WO2009086483A2 (en) | 2007-12-26 | 2009-07-09 | Gel-Del Technologies, Inc. | Biocompatible protein particles, particle devices and methods thereof |
US8378011B2 (en) * | 2007-12-27 | 2013-02-19 | Boston Scientific Scimed, Inc. | Enhanced durability of hydrophilic coatings |
US20110059874A1 (en) * | 2008-03-12 | 2011-03-10 | Marnix Rooijmans | Hydrophilic coating |
EP2103318A1 (en) | 2008-03-20 | 2009-09-23 | Bayer MaterialScience AG | Medical devices with hydrophilic coatings |
EP2103317A1 (en) | 2008-03-20 | 2009-09-23 | Bayer MaterialScience AG | Medical devices with hydrophilic coatings |
EP2110147B1 (en) * | 2008-04-17 | 2011-10-26 | Astra Tech AB | Improved medical device with hydrophilic coating |
EP2285443B1 (en) * | 2008-05-01 | 2016-11-23 | Bayer Intellectual Property GmbH | Catheter balloon drug adherence techniques and methods |
US8602961B2 (en) | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
DE102008025614A1 (en) * | 2008-05-28 | 2009-12-03 | Bayer Materialscience Ag | Hydrophilic polyurethane coatings |
US20110076712A1 (en) * | 2008-06-13 | 2011-03-31 | Xy, Llc. | Lubricious microfludic flow path system |
CH699079A1 (en) * | 2008-07-04 | 2010-01-15 | Arik Zucker | Arrangement consisting of a stent and a package. |
US20100048758A1 (en) * | 2008-08-22 | 2010-02-25 | Boston Scientific Scimed, Inc. | Lubricious coating composition for devices |
DK2331156T3 (en) | 2008-09-04 | 2012-05-29 | Bayer Materialscience Ag | TCD-based hydrophilic polyurethane solutions |
WO2010039247A2 (en) * | 2008-10-03 | 2010-04-08 | Molecular Sensing, Inc. | Substrates with surfaces modified with peg |
DE102008054482A1 (en) | 2008-12-10 | 2010-06-17 | Wacker Chemie Ag | Graft copolymers and their use as low-profile additives |
MX2011007349A (en) * | 2009-01-09 | 2011-08-03 | Dsm Ip Assets Bv | Primer for coating coiled wires. |
US20100188665A1 (en) * | 2009-01-12 | 2010-07-29 | Molecular Sensing, Inc. | Methods and systems for interferometric analysis |
WO2010080710A2 (en) * | 2009-01-12 | 2010-07-15 | Molecular Sensing, Inc. | Sample collection and measurement in a single container by back scattering interferometry |
US20100209475A1 (en) * | 2009-02-19 | 2010-08-19 | Biomet Manufacturing Corp. | Medical implants having a drug delivery coating |
US8454579B2 (en) | 2009-03-25 | 2013-06-04 | Icu Medical, Inc. | Medical connector with automatic valves and volume regulator |
JP5532665B2 (en) * | 2009-04-20 | 2014-06-25 | 株式会社カネカ | Stent delivery system |
US20100268191A1 (en) * | 2009-04-21 | 2010-10-21 | Medtronic Vascular, Inc. | Drug Delivery Catheter using Frangible Microcapsules and Delivery Method |
US8450118B2 (en) | 2009-05-04 | 2013-05-28 | Molecular Sensing, Inc. | Method for detecting binding interactions between membrane proteins and analytes in a homogenous assay |
US8226566B2 (en) | 2009-06-12 | 2012-07-24 | Flowcardia, Inc. | Device and method for vascular re-entry |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
EP2501431B1 (en) * | 2009-11-19 | 2020-01-08 | Wellinq Medical B.V. | Narrow profile composition-releasing expandable medical balloon catheter |
US8287890B2 (en) * | 2009-12-15 | 2012-10-16 | C.R. Bard, Inc. | Hydrophilic coating |
EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
EP2531140B1 (en) * | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
USD644731S1 (en) | 2010-03-23 | 2011-09-06 | Icu Medical, Inc. | Medical connector |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
JP2013526298A (en) * | 2010-05-07 | 2013-06-24 | ケアフュージョン2200、インコーポレイテッド | Catheter allowing variable doses of active agent |
US8758306B2 (en) | 2010-05-17 | 2014-06-24 | Icu Medical, Inc. | Medical connectors and methods of use |
US9638632B2 (en) | 2010-06-11 | 2017-05-02 | Vanderbilt University | Multiplexed interferometric detection system and method |
US8957125B2 (en) | 2010-06-16 | 2015-02-17 | Dsm Ip Assets B.V. | Coating formulation for preparing a hydrophilic coating |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US8541498B2 (en) | 2010-09-08 | 2013-09-24 | Biointeractions Ltd. | Lubricious coatings for medical devices |
US9327101B2 (en) | 2010-09-17 | 2016-05-03 | Abbott Cardiovascular Systems Inc. | Length and diameter adjustable balloon catheter |
WO2012037510A1 (en) | 2010-09-17 | 2012-03-22 | Abbott Cardiovascular Systems Inc. | Length and diameter adjustable balloon catheter |
EP2675274B1 (en) | 2011-02-14 | 2017-05-03 | The Regents of The University of California | SORAFENIB DERIVATIVES AS sEH INHIBITORS |
US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
US8931637B2 (en) * | 2011-05-04 | 2015-01-13 | Cook Medical Technologies Llc | Medical lumen access device assembly including medical lumen access device holder and method of use |
US20130085451A1 (en) * | 2011-09-29 | 2013-04-04 | Tyco Healthcare Group Lp | Plasma-treated dialysis catheter cuff |
US9603615B2 (en) | 2012-01-18 | 2017-03-28 | C.R. Bard, Inc. | Vascular re-entry device |
CN104185661B (en) | 2012-01-18 | 2016-08-17 | 苏尔莫迪克斯公司 | The lubricity medical treatment device coating of low microgranule |
CN104093708B (en) | 2012-02-01 | 2016-11-09 | 加利福尼亚大学董事会 | The acylpiperidine inhibitor of soluble epoxide hydrolase |
US8545951B2 (en) | 2012-02-29 | 2013-10-01 | Kimberly-Clark Worldwide, Inc. | Endotracheal tubes and other polymer substrates including an anti-fouling treatment |
RU2482883C1 (en) * | 2012-03-12 | 2013-05-27 | Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук | Method for preparing fibre polymeric composites with antimicrobial activity |
US9849005B2 (en) * | 2012-04-16 | 2017-12-26 | Biotronik Ag | Implant and method for manufacturing same |
US20130304180A1 (en) | 2012-05-09 | 2013-11-14 | Michael L. Green | Catheter having dual balloon hydraulic actuator |
US9271855B2 (en) | 2012-05-09 | 2016-03-01 | Abbott Cardiovascular Systems Inc. | Catheter having hydraulic actuator with tandem chambers |
US9011513B2 (en) | 2012-05-09 | 2015-04-21 | Abbott Cardiovascular Systems Inc. | Catheter having hydraulic actuator |
US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
JP6549482B2 (en) | 2012-06-01 | 2019-07-24 | サーモディクス,インコーポレイテッド | Device and method for coating a balloon catheter |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US8684963B2 (en) | 2012-07-05 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Catheter with a dual lumen monolithic shaft |
EP2879596A2 (en) | 2012-08-02 | 2015-06-10 | Flowcardia, Inc. | Ultrasound catheter system |
US20140220331A1 (en) | 2013-02-02 | 2014-08-07 | Cosilion LLC | Antimicrobial compositions |
US9623216B2 (en) | 2013-03-12 | 2017-04-18 | Abbott Cardiovascular Systems Inc. | Length and diameter adjustable balloon catheter for drug delivery |
US9326875B2 (en) | 2013-03-13 | 2016-05-03 | Abbott Cardiovascular Systems Inc. | Catheter having a movable tubular structure and method of making |
US10531971B2 (en) | 2013-03-12 | 2020-01-14 | Abbott Cardiovascular System Inc. | Balloon catheter having hydraulic actuator |
US9283101B2 (en) | 2013-03-12 | 2016-03-15 | Abbott Cardiovascular Systems Inc. | Catheter having hydraulic actuator and locking system |
WO2014143197A1 (en) | 2013-03-12 | 2014-09-18 | Abbott Cardiovascular Systems Inc. | Catheter having movable tubular structure and proximal stopper |
JP6172779B2 (en) | 2013-03-12 | 2017-08-02 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Catheter with hydraulic actuator and locking system |
US10420662B2 (en) | 2013-03-12 | 2019-09-24 | Abbott Cardiovascular Systems Inc. | Catheter having movable tubular structure and proximal stopper |
EP2914325A1 (en) | 2013-03-14 | 2015-09-09 | Abbott Cardiovascular Systems Inc. | Stiffness adjustable catheter |
CN105246537A (en) | 2013-03-15 | 2016-01-13 | 雅培心血管系统有限公司 | Length adjustable balloon catheter for multiple indications |
CN103212112B (en) * | 2013-05-06 | 2015-10-07 | 中国热带农业科学院南亚热带作物研究所 | A kind of containing Natural cinnamyl aldehyde anti-inflammation lubricating type catheter and preparation method thereof |
EP2996629B1 (en) | 2013-05-15 | 2021-09-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
JP6034506B2 (en) * | 2013-10-18 | 2016-11-30 | 住友ゴム工業株式会社 | Surface-modified metal and method for modifying metal surface |
CR20160134A (en) | 2013-11-04 | 2016-08-05 | Abbot Cardiovascular Systems Inc | ADJUSTABLE LENGTH BALL CATETER |
ES2941891T3 (en) | 2013-12-11 | 2023-05-26 | Icu Medical Inc | Retention valve |
MX2017002457A (en) * | 2014-08-26 | 2017-05-19 | Bard Inc C R | Urinary catheter. |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
US10124088B2 (en) | 2014-09-29 | 2018-11-13 | Surmodics, Inc. | Lubricious medical device elements |
USD786427S1 (en) | 2014-12-03 | 2017-05-09 | Icu Medical, Inc. | Fluid manifold |
USD793551S1 (en) | 2014-12-03 | 2017-08-01 | Icu Medical, Inc. | Fluid manifold |
JP6154370B2 (en) | 2014-12-26 | 2017-06-28 | 住友ゴム工業株式会社 | Surface-modified metal and method for modifying metal surface |
JP2018506715A (en) | 2015-01-23 | 2018-03-08 | ヴァンダービルト ユニバーシティー | Robust interferometer and method of use |
CN107949403A (en) | 2015-04-16 | 2018-04-20 | 好利司泰公司 | Hydrophilic coating and forming method thereof |
EP3294359B1 (en) * | 2015-05-08 | 2019-09-11 | Koninklijke Philips N.V. | Hydrophilic coating for intravascular devices |
JP6249987B2 (en) * | 2015-05-13 | 2017-12-20 | ルトニックス,インコーポレーテッド | Drug release coating for medical devices |
GB201509919D0 (en) * | 2015-06-08 | 2015-07-22 | Jmedtech Pte Ltd | Coating |
JP6753041B2 (en) | 2015-08-27 | 2020-09-09 | 住友ゴム工業株式会社 | Surface modification Metal and metal surface modification method |
US11174447B2 (en) | 2015-12-29 | 2021-11-16 | Surmodics, Inc. | Lubricious coatings with surface salt groups |
US10342898B2 (en) | 2015-12-29 | 2019-07-09 | Surmodics, Inc. | Lubricious coatings with surface salt groups |
WO2017132483A1 (en) | 2016-01-29 | 2017-08-03 | Vanderbilt University | Free-solution response function interferometry |
CA3015481C (en) | 2016-02-23 | 2021-05-04 | Hollister Incorporated | Medical device with hydrophilic coating |
JP6776029B2 (en) * | 2016-07-06 | 2020-10-28 | テルモ株式会社 | Medical equipment |
EP3484535B1 (en) * | 2016-07-14 | 2022-01-19 | Hollister Incorporated | Hygienic medical devices having hydrophilic coating and methods of forming the same |
JP7066642B2 (en) | 2016-07-18 | 2022-05-13 | メリット・メディカル・システムズ・インコーポレイテッド | Inflatable radial artery compression device |
CN106334219A (en) * | 2016-08-25 | 2017-01-18 | 百诺奥医学科技(苏州)有限公司 | Hyaluronic acid modified hydrophilic lubricating coating, preparation method and applications thereof |
US20180140321A1 (en) | 2016-11-23 | 2018-05-24 | C. R. Bard, Inc. | Catheter With Retractable Sheath And Methods Thereof |
US11596726B2 (en) | 2016-12-17 | 2023-03-07 | C.R. Bard, Inc. | Ultrasound devices for removing clots from catheters and related methods |
US10758256B2 (en) | 2016-12-22 | 2020-09-01 | C. R. Bard, Inc. | Ultrasonic endovascular catheter |
US10582983B2 (en) | 2017-02-06 | 2020-03-10 | C. R. Bard, Inc. | Ultrasonic endovascular catheter with a controllable sheath |
EP3629731A1 (en) | 2017-05-27 | 2020-04-08 | Poly Group LLC | Dispersible antimicrobial complex and coatings therefrom |
EP3638740A1 (en) | 2017-06-16 | 2020-04-22 | Poly Group LLC | Polymeric antimicrobial surfactant |
WO2019163764A1 (en) * | 2018-02-20 | 2019-08-29 | テルモ株式会社 | Medical instrument |
FR3085164B1 (en) * | 2018-08-22 | 2021-02-26 | Natvi | LUBRICATION PROCESS |
WO2020112816A1 (en) | 2018-11-29 | 2020-06-04 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
AU2020348451A1 (en) | 2019-09-20 | 2022-04-21 | Glyscend, Inc. | Substituted phenyl boronic acid containing polymers and methods of use |
CN113663130A (en) * | 2020-05-13 | 2021-11-19 | 脉通医疗科技(嘉兴)有限公司 | Artificial blood vessel and preparation method thereof |
CN114177361A (en) * | 2021-11-22 | 2022-03-15 | 禾木(中国)生物工程有限公司 | Drug balloon and preparation method thereof |
CN114891132A (en) * | 2022-06-28 | 2022-08-12 | 矿冶科技集团有限公司 | High-transparency cationic guar gum and preparation method and application thereof |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3695921A (en) | 1970-09-09 | 1972-10-03 | Nat Patent Dev Corp | Method of coating a catheter |
CS154977B1 (en) | 1971-10-08 | 1974-04-30 | ||
US4055682A (en) | 1971-11-19 | 1977-10-25 | High Voltage Engineering Corporation | Catheter and the method of making |
AU494547B2 (en) | 1972-07-10 | 1977-10-20 | Johnson & Johnson | Hydrophilic random interpolymer compositions and method for making same |
US3886947A (en) | 1973-04-13 | 1975-06-03 | Meadox Medicals Inc | Non-thrombogenic catheter |
NL7707669A (en) | 1977-07-08 | 1979-01-10 | Akzo Nv | METHOD OF COVERING A SUBSTRATE WITH A RADIATION HARDABLE COATING COMPOSITION. |
US4100309A (en) | 1977-08-08 | 1978-07-11 | Biosearch Medical Products, Inc. | Coated substrate having a low coefficient of friction hydrophilic coating and a method of making the same |
CA1109580A (en) * | 1977-11-03 | 1981-09-22 | Kohtaro Nagasawa | Radiation curable resin composition |
SE448544B (en) | 1979-12-05 | 1987-03-02 | Kendall & Co | WATER ABSORPTION COMPOSITION AND USE THEREOF AS A CARRIER FOR A MEDICINE |
US4656252A (en) | 1980-01-24 | 1987-04-07 | Giese Roger W | Amidobiotin compounds useful in a avidin-biotin multiple layering process |
USRE31712E (en) * | 1980-01-24 | 1984-10-23 | Biochemical avidin-biotin multiple-layer system | |
US4282287A (en) | 1980-01-24 | 1981-08-04 | Giese Roger W | Biochemical avidin-biotin multiple-layer system |
IL63638A0 (en) * | 1980-09-16 | 1981-11-30 | Aligena Ag | Semipermeable composite membranes,their manufacture and their use |
US4530974A (en) | 1981-03-19 | 1985-07-23 | Board Of Regents, The University Of Texas System | Nonthrombogenic articles having enhanced albumin affinity |
US4373009A (en) | 1981-05-18 | 1983-02-08 | International Silicone Corporation | Method of forming a hydrophilic coating on a substrate |
US4500688A (en) | 1982-04-20 | 1985-02-19 | Petrarch Systems Inc. | Curable silicone containing compositions and methods of making same |
SE430695B (en) | 1982-04-22 | 1983-12-05 | Astra Meditec Ab | PROCEDURE FOR THE PREPARATION OF A HYDROPHILIC COATING AND ACCORDING TO THE PROCEDURE OF MEDICAL ARTICLES |
US4459326A (en) | 1982-05-19 | 1984-07-10 | Hillyard Enterprises, Inc. | Coating of synthetic surfaces with water-based coatings |
US4722906A (en) | 1982-09-29 | 1988-02-02 | Bio-Metric Systems, Inc. | Binding reagents and methods |
US4973493A (en) | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US5002582A (en) | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
US4521564A (en) | 1984-02-10 | 1985-06-04 | Warner-Lambert Company | Covalent bonded antithrombogenic polyurethane material |
DE3582754D1 (en) | 1984-06-04 | 1991-06-13 | Terumo Corp | MEDICAL TOOL AND PRODUCTION METHOD. |
US5037677A (en) | 1984-08-23 | 1991-08-06 | Gregory Halpern | Method of interlaminar grafting of coatings |
US5023114A (en) | 1984-08-23 | 1991-06-11 | Gregory Halpern | Method of hydrophilic coating of plastics |
SE444950B (en) * | 1984-09-28 | 1986-05-20 | Ytkemiska Inst | COVERED ARTICLE, PROCEDURES AND METHODS OF PRODUCING THEREOF AND USING THEREOF |
GB2166977B (en) | 1984-11-08 | 1988-04-20 | Mitsubishi Monsanto Chem | Medical material and process for its production |
SE8504501D0 (en) | 1985-09-30 | 1985-09-30 | Astra Meditec Ab | METHOD OF FORMING AN IMPROVED HYDROPHILIC COATING ON A POLYMER SURFACE |
US4729914A (en) | 1985-12-30 | 1988-03-08 | Tyndale Plains-Hunter Ltd. | Hydrophilic coating and substrate coated therewith |
US5108923A (en) | 1986-04-25 | 1992-04-28 | Collaborative Research, Inc. | Bioadhesives for cell and tissue adhesion |
GB8611838D0 (en) | 1986-05-15 | 1986-06-25 | Yarsley Technical Centre Ltd | Hydrophilic copolymers |
US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
US5263992A (en) | 1986-10-17 | 1993-11-23 | Bio-Metric Systems, Inc. | Biocompatible device with covalently bonded biocompatible agent |
US5100689A (en) | 1987-04-10 | 1992-03-31 | University Of Florida | Surface modified surgical instruments, devices, implants, contact lenses and the like |
US5094876A (en) | 1987-04-10 | 1992-03-10 | University Of Florida | Surface modified surgical instruments, devices, implants, contact lenses and the like |
US5290548A (en) | 1987-04-10 | 1994-03-01 | University Of Florida | Surface modified ocular implants, surgical instruments, devices, prostheses, contact lenses and the like |
US4870160A (en) | 1987-08-19 | 1989-09-26 | Regents Of The University Of Minnesota | Polypeptides with laminin activity |
US5294551A (en) | 1987-08-25 | 1994-03-15 | Regents Of The University Of Minnesota | Cell culture substrate coated with polypeptides having fibronectin activity |
US5116368A (en) | 1987-08-25 | 1992-05-26 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
US5171271A (en) | 1987-08-25 | 1992-12-15 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
US5147797A (en) | 1987-08-25 | 1992-09-15 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
US4876332A (en) | 1987-10-08 | 1989-10-24 | Regents Of The Univeristy Of Minnesota | Polypeptides with type IV collagen activity |
CA1312277C (en) | 1987-12-18 | 1993-01-05 | Richard C. Sutton | Avidin- and biotin-immobilized reagents, analytical elements and methods of use |
DE68927479T2 (en) | 1988-05-02 | 1997-04-03 | Phanos Tech Inc | CONNECTIONS, COMPOSITIONS AND METHOD FOR BINDING ORGANIC AFFECTION SUBSTANCES TO SURFACE MEMBRANES OF BIOPARTICLES |
US5167960A (en) | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
EP0389632A4 (en) | 1988-08-09 | 1990-12-27 | Toray Industries, Inc. | Slippery medical material and process for its production |
US5840293A (en) | 1988-11-16 | 1998-11-24 | Advanced Polymer Systems, Inc. | Ionic beads for controlled release and adsorption |
US4978481A (en) * | 1989-01-13 | 1990-12-18 | Ciba-Geigy Corporation | Process for the encapsulation of preformed substrates by graft copolymerization |
US5091205A (en) | 1989-01-17 | 1992-02-25 | Union Carbide Chemicals & Plastics Technology Corporation | Hydrophilic lubricious coatings |
JP2927942B2 (en) | 1989-01-27 | 1999-07-28 | オーストラリアン メンブレイン アンド バイオテクノロジィ リサーチ インスティチュート | Gating of receptor membranes and ionophores |
US5389518A (en) | 1989-02-03 | 1995-02-14 | Commonwealth Scientific And Industrial Research Organisation | Monoclonal antibodies directed against vitronectin and fibronectin, and uses thereof |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5041100A (en) | 1989-04-28 | 1991-08-20 | Cordis Corporation | Catheter and hydrophilic, friction-reducing coating thereon |
US5026607A (en) | 1989-06-23 | 1991-06-25 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5188959A (en) | 1989-09-28 | 1993-02-23 | Trustees Of Tufts College | Extracellular matrix protein adherent t cells |
US5278063A (en) | 1989-09-28 | 1994-01-11 | Board Of Regents The University Of Texas System | Chemical modification of promote animal cell adhesion on surfaces |
US5118779A (en) * | 1989-10-10 | 1992-06-02 | Polymedica Industries, Inc. | Hydrophilic polyurethane elastomers |
US5049403A (en) * | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5081031A (en) | 1989-12-14 | 1992-01-14 | Regents Of The University Of Minnesota | Synthetic polypeptide with type iv collagen activity |
US5152784A (en) | 1989-12-14 | 1992-10-06 | Regents Of The University Of Minnesota | Prosthetic devices coated with a polypeptide with type IV collagen activity |
US5135516A (en) | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
DK146790D0 (en) * | 1990-06-15 | 1990-06-15 | Meadox Surgimed As | PROCEDURE FOR THE PREPARATION OF A FERTILIZER COATING COATING AND MEDICAL INSTRUMENT WITH COATING COATING |
US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
US5160790A (en) * | 1990-11-01 | 1992-11-03 | C. R. Bard, Inc. | Lubricious hydrogel coatings |
US5132108A (en) | 1990-11-08 | 1992-07-21 | Cordis Corporation | Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents |
US5102420A (en) | 1990-11-14 | 1992-04-07 | Ethicon, Inc. | Suture coated with a polyetheramide |
US5295978A (en) | 1990-12-28 | 1994-03-22 | Union Carbide Chemicals & Plastics Technology Corporation | Biocompatible hydrophilic complexes and process for preparation and use |
JP2957021B2 (en) | 1991-01-25 | 1999-10-04 | テルモ株式会社 | Medical material, medical device, and method of manufacturing medical material |
EP0521605A3 (en) | 1991-05-16 | 1993-03-10 | Ioptex Research Inc. | Biocompatible lubricious grafts |
EP0558697A1 (en) | 1991-06-28 | 1993-09-08 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
EP0605466B1 (en) | 1991-08-23 | 2002-08-07 | Board Of Regents Of The University Of Nebraska | Method and compositions for cellular reprogramming |
US5654284A (en) | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
EP0572624A4 (en) | 1991-12-18 | 1994-07-06 | Scimed Life Systems Inc | Lubricous polymer network |
US5756476A (en) | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
US5571166A (en) | 1992-03-19 | 1996-11-05 | Medtronic, Inc. | Method of making an intraluminal stent |
US5512474A (en) | 1992-05-29 | 1996-04-30 | Bsi Corporation | Cell culture support containing a cell adhesion factor and a positively-charged molecule |
DK172393B1 (en) | 1992-06-10 | 1998-05-18 | Maersk Medical As | Process for producing an article having friction-reducing surface coating, coating material for use in the manufacture of such article, and using an osmolality-increasing compound in slurry or emulsified form in the coating material |
US5383928A (en) | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
US5656609A (en) | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
US5409731A (en) * | 1992-10-08 | 1995-04-25 | Tomei Sangyo Kabushiki Kaisha | Method for imparting a hydrophilic nature to a contact lens |
WO1994009128A1 (en) | 1992-10-22 | 1994-04-28 | Mallinckrodt Medical, Inc. | Therapeutic treatment for inhibiting vascular restenosis |
US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
US5350800A (en) | 1993-01-19 | 1994-09-27 | Medtronic, Inc. | Method for improving the biocompatibility of solid surfaces |
SE500964C2 (en) | 1993-01-19 | 1994-10-10 | Medicarb Ab | Solid surface modified carrier wherein the modification is effected by a primer containing a polysaccharide and process for producing such a carrier |
CA2114697C (en) | 1993-02-08 | 2006-06-13 | Kenichi Shimura | Medical tool having lubricious surface in a wetted state and method for production thereof |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5531715A (en) | 1993-05-12 | 1996-07-02 | Target Therapeutics, Inc. | Lubricious catheters |
NO931809L (en) * | 1993-05-19 | 1994-11-21 | Norsk Hydro As | hemophilia |
DE69407292T2 (en) | 1993-06-30 | 1998-06-25 | Genentech Inc | METHOD FOR PRODUCING LIPOSOME |
US5639872A (en) | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
US5663450A (en) | 1993-08-17 | 1997-09-02 | Cv Therapeutics | Macrophage lipid chemoattractant |
AU680996B2 (en) | 1993-12-17 | 1997-08-14 | Novavax, Inc. | Method of transmitting a biologically active material to a cell |
US5470307A (en) | 1994-03-16 | 1995-11-28 | Lindall; Arnold W. | Catheter system for controllably releasing a therapeutic agent at a remote tissue site |
US5505713A (en) | 1994-04-01 | 1996-04-09 | Minimed Inc. | Indwelling catheter with stable enzyme coating |
CA2188563C (en) | 1994-04-29 | 2005-08-02 | Andrew W. Buirge | Stent with collagen |
US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5681278A (en) | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US5652225A (en) | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US5643580A (en) | 1994-10-17 | 1997-07-01 | Surface Genesis, Inc. | Biocompatible coating, medical device using the same and methods |
US5519020A (en) | 1994-10-28 | 1996-05-21 | The University Of Akron | Polymeric wound healing accelerators |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5665591A (en) | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US5660855A (en) | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
US5575818A (en) | 1995-02-14 | 1996-11-19 | Corvita Corporation | Endovascular stent with locking ring |
US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US5665077A (en) | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5567828A (en) | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
US5672638A (en) * | 1995-08-22 | 1997-09-30 | Medtronic, Inc. | Biocompatability for solid surfaces |
US5607475A (en) * | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
US5603991A (en) | 1995-09-29 | 1997-02-18 | Target Therapeutics, Inc. | Method for coating catheter lumens |
US5728420A (en) * | 1996-08-09 | 1998-03-17 | Medtronic, Inc. | Oxidative method for attachment of glycoproteins to surfaces of medical devices |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US5811151A (en) * | 1996-05-31 | 1998-09-22 | Medtronic, Inc. | Method of modifying the surface of a medical device |
US5916585A (en) | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US5800412A (en) | 1996-10-10 | 1998-09-01 | Sts Biopolymers, Inc. | Hydrophilic coatings with hydrating agents |
-
1998
- 1998-01-30 US US09/016,694 patent/US6221425B1/en not_active Expired - Lifetime
- 1998-12-31 WO PCT/US1998/027731 patent/WO1999038545A1/en active Application Filing
- 1998-12-31 AU AU20192/99A patent/AU2019299A/en not_active Abandoned
-
1999
- 1999-01-29 AU AU25677/99A patent/AU745979B2/en not_active Ceased
- 1999-01-29 AT AT99905536T patent/ATE330646T1/en not_active IP Right Cessation
- 1999-01-29 WO PCT/US1999/001919 patent/WO1999038546A1/en active IP Right Grant
- 1999-01-29 DE DE69932034T patent/DE69932034T2/en not_active Expired - Lifetime
- 1999-01-29 JP JP2000529277A patent/JP2002501788A/en not_active Withdrawn
- 1999-01-29 US US09/240,914 patent/US6287285B1/en not_active Expired - Lifetime
- 1999-01-29 CA CA002316223A patent/CA2316223A1/en not_active Abandoned
- 1999-01-29 EP EP99905536A patent/EP1051208B1/en not_active Expired - Lifetime
-
2001
- 2001-07-25 US US09/915,413 patent/US6656517B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69932034T2 (en) | 2007-06-28 |
EP1051208B1 (en) | 2006-06-21 |
ATE330646T1 (en) | 2006-07-15 |
AU745979B2 (en) | 2002-04-11 |
AU2019299A (en) | 1999-08-16 |
EP1051208A1 (en) | 2000-11-15 |
US6287285B1 (en) | 2001-09-11 |
JP2002501788A (en) | 2002-01-22 |
US20020002353A1 (en) | 2002-01-03 |
US6656517B2 (en) | 2003-12-02 |
WO1999038545A1 (en) | 1999-08-05 |
US6221425B1 (en) | 2001-04-24 |
AU2567799A (en) | 1999-08-16 |
WO1999038546A1 (en) | 1999-08-05 |
DE69932034D1 (en) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2316223A1 (en) | Hydrophilic coating for an intracorporeal medical device | |
US20080004280A1 (en) | Heterocyclic topoisomerase poisons | |
US6992088B2 (en) | Nitro and amino substituted heterocycles as topoisomerase I targeting agents | |
US20080045538A1 (en) | Nitro and amino substituted topoisomerase agents | |
US20060058306A1 (en) | Solubilized topoisomerase poison agents | |
US7049315B2 (en) | Solubilized topoisomerase poisons | |
US6989387B2 (en) | Nitro and amino substituted topoisomerase agents | |
US7517867B2 (en) | Topoisomerase-targeting agents | |
US6740650B2 (en) | Heterocyclic cytotoxic agents | |
WO2001032631A2 (en) | Heterocyclic cytotoxic agents | |
US20050010046A1 (en) | Topoisomerase poison agents | |
US6221892B1 (en) | Heterocyclic topoisomerase poisons | |
MXPA00006499A (en) | Heterocyclic topoisomerase poisons | |
CZ20002497A3 (en) | Heterocyclic compounds | |
MXPA00007838A (en) | Heterocyclic topoisomerase poisons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |